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ABSTRACT 
 The high cost and the long time required to bring drugs into commerce is driving 
efforts to repurpose FDA approved drugs—to find new uses for which they weren’t 
intended, and to thereby reduce the overall cost of commercialization, and shorten the lag 
between drug discovery and availability. In comparison to traditional drug repositioning, 
which relies on serendipitous clinical discoveries, computational methods can systemize 
the drug search and facilitate the drug development timeline even further. In this 
dissertation, I report on the development, testing and application of a promising new 
approach to drug repositioning. 
 This novel computational drug repositioning method is based on mining a human 
functional linkage network for inversely correlated modules of drug and disease gene 
targets. Functional linkage network is an evidence-weighted network that provides a 
quantitative measure of the degree of functional association among any set of human 
genes. The method takes account of multiple information sources, including gene 
mutation, gene expression, and functional connectivity and proximity of within module 
genes. 
		 v 
 The method was used to identify candidates for treating breast and prostate cancer. 
We found that (i) the recall rate for FDA approved drugs for breast and (prostate) cancer 
is 20/20 (10/11), while the rates for drugs in clinical trials were 131/154 and (82/106); (ii) 
the Area Under the ROC Curve performance substantially exceeds that of two 
comparable previously published methods; (iii) preliminary in vitro studies indicate that 
5/5 identified breast cancer candidates have therapeutic indices superior to that of 
Doxorubicin in Luminal-A (MCF7) and Triple-Negative (SUM149) breast cancer cell 
lines. I briefly discuss the biological plausibility of the candidates at a molecular level in 
the context of the biological processes that they mediate. 
 In conclusion, our method provides a unique way of prioritizing disease causal 
genes and identifying drug candidates for repositioning, based on innovative 
computational method. The method appears to offer promise for the identification of 
multi-targeted drug candidates that can correct aberrant cellular functions. In particular 
the computational performance exceeded that of existing computational methods. The 
approach has the potential to provide a more efficient drug discovery pipeline. 
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CHAPTER 1 Introduction 
1.1 The value of drug repositioning 
The conventional drug discovery pipeline is inefficient and expensive. A standard 
research and development (R&D) strategy for a new drug comprises basic research for 
disease biomarker identification, drug design, safety and efficacy tests in preclinical and 
clinical tests, and finally Phase III trials performed to monitor side effects and compare 
the drug candidate to similar compounds on the market. In the past, this process took up 
to 10-15 years [1]. In addition, since 2008, the failure rate for drugs in Phase II and III 
has been rising. Phase II success rate is currently 18%, lower than in any other phases of 
drug development [1, 2]. The lengthy process and high failure rate of clinical trials have 
contributed to the high cost for drug development. The limited drug efficacy shown in the 
failures in Phase II can be ascribed to the flaws in the initial step of disease 
biomarker/drug target identification; the basis for drug selection relies primarily on 
finding one drug that affects one protein or one gene, it ignores protein interactions and 
functional insight of drug action mechanisms that can potentially correct disease 
phenotypes. 
One way to reduce costs is by repositioning or repurposing FDA-approved drugs; i.e. 
establishing their efficacy for diseases or conditions for which they weren’t originally 
intended. With this alternative strategy, drug developer can bypass 40% of the overall 
cost of bringing a drug to market [3]. Since approved drugs have known 
pharmacokinetics and safety profiles and are often approved by regulatory agencies for 
human use, any newly identified use can be rapidly evaluated in clinical tests. This 
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alternative development typically lasts about 2 years and costs about $ 17 million [3]. It 
thereby reduces the overall cost of commercialization, and shortens the lag between drug 
discovery and availability [3]. 
Traditionally, drug repositioning has used the mechanistic knowledge of drug target and 
unintended side effect in order to infer a new disease application for existing drugs. 
These approaches are not systematic but often rely on serendipity. Through clinical 
observations, drugs can be noted to have side effects that could positively ameliorate 
symptoms of other diseases. Among the successes of this approach are sildenafil, 
originally developed as a cardiovascular drug [4] and repositioned to treat erectile 
dysfunction; and zidovudine (AZT), originally developed as an anticancer drug [5], and 
repositioned for the treatment of HIV. These discoveries, though serendipitous, motivated 
more systematic approaches which might amplify the number of discoveries many-fold.  
 
1.2 Current computational drug repositioning approaches 
Systematic approaches generally begin with some form of computer based screening to 
generate large numbers of plausible candidates [6]. Adoption of computational 
methodologies to reposition drugs can systemize traditional drug repositioning and has 
become mainstream [7]. It can facilitate the drug development pipeline even further by 
prioritizing repositioned drug candidates for subsequent validations ranging from 
preclinical to clinical validations. 
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Many current computational strategies exploit shared similarities among drugs or 
diseases and infer similar therapeutic applications or drug selections. Drug similarities 
include chemical structures [8-10], drug-induced phenotypic side effects [8, 11], 
molecular activities [12]. Disease similarities include phenotypic similarity constructed 
by identifying similarity between MeSH terms [13] from Online Mendelian Inheritance 
in Man (OMIM) database [14]; 2) semantic phenotypic similarity [8]. The efficacy of the 
candidates generated by such approaches would not exceed that of existing drugs since 
the disease biomarkers remain the same. 
A more general approach searches for disease (Gene Expression Omnibus, GEO) and 
drug (Connectivity Map, CMap) induced transcriptional profiles that are inversely 
correlated [15-19]. Strong anti correlation between the gene expression profiles of an 
FDA approved drug and those of a disease for which it was not intended identifies the 
drug as a candidate for repositioning. This procedure, though useful, is relatively agnostic 
with respect to the functional relations between profiles (the ordered lists of perturbed 
genes). A drug identified this way is limited in that it is not informed by cellular function, 
but simply targets a group of generally non-interacting differentially expressed genes. 
 
1.3 Method of functional modules (MFM) 
The idea underlying our method, which we refer to as the method of functional modules 
(MFM), is to impose the condition that candidates must affect the same cellular functions 
in opposite ways, and to use information about DNA as well as RNA. In particular we 
search for drugs that strongly perturb sets of genes having the following properties: (i) 
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they share a strong functional relationship (ii) they are mutated in the disease state (iii) 
their expression is highly perturbed by the disease (iv) they are within significantly 
perturbed pathways of diseases. Functional association is based on position in a human 
functional linkage network (FLN) [20]—an evidence weighted network that provides a 
quantitative measure of the degree of functional association among any set of human 
genes. This means the method integrates multiple sources of evidence such as protein-
protein interactions and is not limited to catalogued functional associations, e.g. KEGG, 
but uses a general approach to find functional modules.  
We used genome-wide transcriptional data for more than 3500 compounds provided by 
Library of Integrated Network-Based Cellular Signatures (LINCS) [21] and identified 
519 and (410) repositioned drug candidates for breast and (prostate) cancer.  We also 
compared the accuracy of our method with that of comparable approaches [16, 18] (see 
2.2 Results). We applied CMap datasets and ranked bioactive compounds using different 
methods, and then compared the predictability of the ranked lists of compounds (see 2.1 
Methods). We then presented evidence that a set of disease mutated genes and their 
nearest FLN neighbors (mutation associated genes (MAGs), see 2.1 Methods) provided 
more functional insight than a set of differentially expressed genes in the disease.  
In addition to these computational assessments, in vitro viability tests confirmed that 5/5 
our predicted breast cancer drug candidates had therapeutic indices superior than that of 
Doxorubicin--an FDA-approved drug for breast cancer--against Luminal-A subtype 
(MCF7) and Triple-Negative subtype (SUM149) breast cancer cell lines.  
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CHAPTER 2 Identification of repositioned drug candidates  
2.1 Methods and materials 
The method built non-incrementally on the work of Shigemizu et al [18]. In particular: (i) 
we took account of information on mutations (DNA) as opposed to just expression 
(RNA); and (ii) we took account of functional information by using a so-called FLN [20], 
as explained below. Specifically, we annotated mutated genes on the FLN [20], and 
identified and eliminated all genes that 1) are not within a specified distance of a mutated 
gene (the functional module constraint); 2) have a differential expression below some 
threshold (the disease condition constraint); 3) are not in pathways that distinguish the 
cancer/normal phenotype. 
An FLN [20] is represented as a network of nodes (genes/proteins) connected by links 
whose weights are proportional to the likelihood that the connected nodes share  common 
biological functions. We set a threshold on linkage weight so as to exclude approximately 
95% of the neighbors of any given node, leaving clusters of functionally related aberrant 
genes. We carried out the procedure twice, once starting with mutated genes and their 
first nearest neighbors, and then with mutated genes and their first and second nearest 
neighbors. 
We considered each drug in turn and identified two FLN landscapes: one defined by 
genes that are up-regulated by the disease and down regulated by the drugs (Up regulated 
Cancer gene, Down regulated Bioactive target gene--UCDB) and, the other defined by 
genes that are down regulated by disease and up regulated by the drug (DCUB). Each 
landscape was thus an interconnected set of drug and disease perturbed genes. Finally we 
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assigned a score, mutual predictability (discussed below), which measured the 
connectivity within each landscape, which is roughly speaking the extent to which the 
drug and disease genes sets are correlated. The greater the relationship, the higher the 
likelihood that the drug is a viable candidate for repositioning. The methodology is 
summarized in Fig 1. The specifics follow. 
2.1.1 Analytical workflow 
 
Figure 1. Analytical workflow 
(1) After mapping mutated genes to the FLN, identify the functional neighbors that are up 
or down regulated (DEG: differentially expressed genes) and within significantly 
enriched disease pathways (FDR<0.05). (2) Map the genes that are down or up regulated 
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by drug candidates to the FLN (3) Compute the MP score; i.e. the significance of the 
functional overlap between the drug and disease perturbed genes (see text). (4) Rank the 
compounds according to the MP score. (5) Compute the sensitivity and specificity of the 
ranked list of compounds. (6) Repeat the process with different groups of MAG and DRG 
generated by looping over the parameters (m & k). (7) Choose the parameter set that has 
highest sensitivity and specificity. (8) The drug candidates are chosen form the ranked list 
generated by the best parameter set. (9) The top ranked drug candidates are chosen for in 
vitro experimental validation. 
2.1.2 Data sources 
2.1.2.1 Mutation associated genes (MAG) 
The procedure maps to the FLN, known mutated drivers for the disease of interest, and 
their first nearest neighbors. It then sets the linkage threshold to 0.2, eliminating 95% of 
the links and leaving gene clusters each of which is relatively homogeneous functionally. 
The remaining genes are further selected by 1) setting a threshold on transcription level; 2) 
filtering out the genes that are not in pathways that distinguish phenotype (i.e. cancer 
from normal--see 2.1.2.1.3 Pathway enrichment analysis). As indicated below we were 
left with relatively small gene sets at the end of the process. In order to identify well-
correlated drug-disease gene sets, the definitions of up- and down-regulated genes were 
not tightly constrained. In particular, we looped through m sets of various sizes, ranging 
from the 1000 most up-regulated genes, to the top half of the total number of genes in our 
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universe--which depends on the number of probes on the chip--in increments of 2,000. A 
similar procedure was followed for the most down-regulated genes.   
Similar networks were obtained for each member of our universe of bioactive compounds. 
A drug was ranked in accord with the intersection between its functional network and the 
disease functional network, as described below. The procedure was then repeated, by 
starting with first and second nearest neighbors. 
2.1.2.1.1 Well-documented mutated genes 
We obtained 40 breast cancer and prostate cancer driver genes, and 69 leukemia driver 
genes, from the Online Mendelian Inheritance in Man (OMIM) 
(http://www.ncbi.nlm.nih.gov/omim) [14]. 
2.1.2.1.2 Transcript levels 
The differentially expressed genes used to filter the MAG were obtained from the 
Illumina HiSeq 2000 RNA Sequencing platform for 108 breast and 51 prostate paired 
tumor and normal samples, downloaded from the TCGA portal 
(http://cancergenome.nih.gov/). Differential expression data in response to leukemia 
(GSE1159, GSE9476) were obtained from the National Center for Biotechnology 
Information (NCBI) Gene Expression Omnibus (GEO) 
(http://www.ncbi.nlm.nih.gov/geo/). The ranked list of differentially expressed genes was 
generated using edgeR [22] and a t-statistic. The final number of MAG ranged from 75 to 
1074 for breast cancer; 15 to 460 for prostate cancer; and 46 to 772 for leukemia. 
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2.1.2.1.3 Pathway enrichment analysis 
We used the PWEA [23] software package to identify significantly perturbed pathways in 
the disease expression profiles described above.  
2.1.2.2 Drug response genes (DRG) 
The top (up-regulated) and bottom (down-regulated) k most differentially expressed 
genes in response to bioactive compounds in disease cell lines were selected as DRG. We 
restricted the number of up (down)-regulated DRG to be within +/- 500 genes of the 
matched down (up)-regulated MAG. For example, if 500 up-regulated MAG are in an 
FLN cluster, k would from a low of 100 to a high of 1000 in increments of 100.  
2.1.2.2.1 Bioactive compounds 
2.1.2.2.1.1 Library of Integrated Cellular Signature (LINCS) 
We downloaded 55,128 and 52,767 expression profiles of bioactive compounds treated in 
MCF7 (breast cancer) and PC-3 (prostate cancer) cell lines, from LINCS (level 4) 
(http://www.lincscloud.org/) [20]. LINCS contains expression data for 10 cancer cell 
lines treated with 20,413 small compounds, including 1300 FDA drugs. It’s the large-
scale transcriptomic data of drug response and a key source of data for repositioned drug 
identifications. LINCS profiles are generated using 3,678 and 4,228 bioactive compounds 
for breast cancer and prostate cancer, respectively, each compound typically applied at 6 
different concentrations (0.0003-177 µM) and 2 time points (6 and 24 hours). Twenty of 
the 3678 (11 of 4228) were FDA approved drugs for breast (prostate) cancer. We retained 
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the expression profile of a compound that produced maximal mutual predictability score 
before ranking the compounds.  
2.1.2.2.1.2 Connectivity Map 
For comparing the performance of our method with other methods that used CMap 
datasets, we obtained ranked lists of differentially expressed genes in response to 1251 
and 1079 compounds treated in breast cancer (MCF7) and myelogenous leukemia cell 
lines (HL60), respectively (connectivity map (CMap) build 02 [16], 
https://www.broadinstitute.org/cmap). Eight of the 1251, and 6 of 1079 were FDA 
approved drugs for breast cancer and prostate cancer respectively. 
 
2.1.3 Mutual predictability 
We used mutual predictability [4] to score the correlation between mutation associated 
genes (MAG) and drug response genes (DRG). In essence, mutual predictability is a 
measure of the degree to which MAG can be used as seed genes to predict DRG 
(predictability M-D), and vice versa (predictability D-M). The mutual predictability of 
the two sets measures the extent to which genes in one set can be used to identify (predict) 
genes in the other [20]. A disease drug pair with high mutual predictability has a strong 
functional relation; the higher the score, the stronger the relation. 
To quantify the predictability M-D, we use MAG as seeds, and score and rank each gene 
connected to a seed using the disease mutual predictability score Si: 
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where wij weights the link between gene i and seed j, and the score is 0 if there is no seed 
connection. We then generate an ROC (sensitivity plotted against 1- specificity) and use 
the area under the curve (AUCM-D) as a measure of association between the two curves.  
We obtained the sensitivity and specify variation by using a series of cutoffs on the 
ranked list. The number of true positives is taken to be the number of DRG above a 
particular cutoff; the number of true negatives is the number of non-DRG below the 
cutoff; the number of false positives is the number of non-DRG above the cutoff, and the 
false negatives are the number of DRG below the cutoff. AUC scores range from 0 and 1, 
with 0.5 and 1.0 indicating random and perfect predictive performance, respectively.  
AUCD-M as a measure of predictability D-M is similarly calculated. The mutual 
predictability between MAG and DRG is then defined as the geometric mean of AUCD-M 
and AUCM-D: 
Mutual Predictability (MAG and DRG) = AUCD − M × AUC M − D 
Each bioactive compound is thereby ranked by its mutual predictability score.  
2.1.4 Evaluation of predictability 
2.1.4.1 Statistical validation 
We determined the extent to which FDA approved cancer drugs were enriched in our 
ranked list by again calculating an AUC as indicated above. Briefly, focus on a position t 
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from the top. The ratio of FDA approved drugs for target disease at or above position t, to 
total drugs at or above t is counted as TP; the ratio of non-FDA approved drugs below t to 
total drugs below t is TN. The running index t is varied to produce a ROC, and the area 
under the curve (AUC) is used as a measure of predictability. This is of course a non-
normalized result, but as we now indicate it is used only in a relative way, to compare 
different parameter sets.  
2.1.4.1.1 Parameter optimization 
Each set of parameters (rank cutoffs m & k for filtering MAG and selecting DRG) 
generated different ranked lists of bioactive compounds. We computed the AUC score 
using the ranked list, and chose the best set of parameters based on the maximum AUC 
score. Repositioned drug candidates were selected from the ranked list generated by the 
best parameter set. After optimization, the best parameters  (number of MAG and DRG 
(MAG/DRG)) are 237/700 (UCDB) and 75/100 (DCUB) for breast cancer; and 333/100 
(UCDB) and 46/100 (DCUB) for prostate cancer.  
For the ranked list, the significance of the mutual predictability scores for each compound 
was estimated by randomly selecting a set of n DRG, computing the mutual predictability 
score given the MAG, repeating the process 100,000 times to generate a null distribution, 
and then estimating the probability that our observation was obtained by chance. We 
computed the false discovery rate (FDR) for individual compounds by calculating the 
expected number of false positives, given the actual distribution of mutual predictability 
scores and the null distribution. 
		
13 
We assessed the significance of the best AUC score by randomly selecting from LINCS, 
20 out of 3678 drugs for breast cancer and 11 out of 4228 for prostate cancer as true 
positives. For CMap, we randomly selected 8 out of 1251 drugs for breast cancer; 6 out 
of 1079 for leukemia; and 7 out of 1182 for prostate cancer. We then computed the AUC 
for each parameter set, repeated the process 100,000 times and generated a null 
distribution. The p-value was used to estimate FDR for multiple tests. 
2.1.4.1.2 Comparison with other methods 
We applied the methods that used CMap data to breast cancer and leukemia and 
compared them with MFM. 
 
2.1.4.1.2.1 Connectivity map (CMap) [16] 
We queried the 50 to 500 (in increments of 50) up- and down-regulated signature genes 
of breast cancer (MCF7), leukemia (HL60) and prostate cancer (PC3) on 
(https://www.broadinstitute.org/cmap/newQuery?servletAction=querySetup&queryType
=quick), and obtained ranked lists of bioactive compounds. The disease signature genes 
(FDR<0.05) were generated from the same expression data used for MFM, as described 
in 2.1.2.1.2 Transcript levels. The total number of compounds and the corresponding cell 
lines were the same as those were used for MFM. Then we followed the same procedure 
as that was used for MFM to assess the performance. The highest AUC score was 
selected for comparison. 
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2.1.4.1.2.2 Shegemizu et al [18] 
We used the same expression profiles (GDS2617, GDS2908 and GDS1439) and 
parameters (1200 and 1400 for UCDB and DCUB for breast cancer; 700 and 800 for 
UCDB and DCUB for leukemia; 5200 and 4200 for UCDB and DCUB for prostate 
cancer) reported in the [18] to generate ranked lists of compounds. Performance was 
assessed with the same procedure used for MFM. 
2.1.4.2 Experimental validation 
2.1.4.2.1 Cell cultures and reagents 
Cell lines MCF7, SUM149 and MCF10A were obtained from ATCC (American Type 
Culture Collection, Manassas, VA) and maintained as recommended. The growth 
medium was supplemented with 10% fetal bovine serum (FBS), 50 units/ml of penicillin 
and streptomycin, and incubated at 37 ˚C with 5% carbon dioxide. Dimethyl sulfoxide 
(DMSO), at 0.2%, was used as the vehicle control. 
2.1.4.2.2 MTT assay 
Metabolic activity of MCF7, MCF10A and SUM149 cells treated with vehicle (0.1% 
DMSO) or repositioned drug candidates was assessed with the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay. Cells were placed in 96-
well plates and treated for 24 hours with drugs with concentrations ranging from 0-1000 
µM, then assayed for metabolic activity. 10 µl of MTT solution (10 mg/ml in PBS) was 
added to each well and incubated for an additional 3 hrs. The medium was then replaced 
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with 200 µl of DMSO. Absorbance was determined at 570 nm (experimental absorbance 
and 690 nm (background absorbance) by an ELISA plate reader. The inhibitory effect of 
drug candidates was expressed as the relative metabolic activity (% control) and 
calculated as shown below. The relative viability was calculated as relative viability = 
(experimental absorbance - background absorbance)/ (absorbance of vehicle controls - 
background absorbance of vehicle controls) × 100 % 
 
2.2 Results 
We screened repositioned drug candidates by using mutual predictability [20] to score 
correlation between mutation-associated genes up-regulated in disease samples and genes 
down-regulated by bioactive compounds (DCUB), and vice versa (UCDB). Since a high 
mutual predictability score indicates strong functional linkage between sets of disease 
and drug related genes, our hypothesis is that candidate drugs so identified have potential 
to correct the sets of disease genes and have therapeutic effect on the disease.  
 
2.2.1 Identification of repositioned drug candidates for breast cancer and prostate cancer 
using LINCS 
We performed analysis on the most updated data of gene expression signatures of 
bioactive compounds from LINCS [21]. We evaluated the significance of mutual 
predictability score of each compound, and FDRs as explained under 2.1 Methods.  
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2.2.2 Statistics of significant bioactive compounds 
2.2.2.1 Breast cancer   
As shown in Table 1, we detected 2435 bioactive compounds from correlation between 
mutation-associated genes up-regulated in disease samples and genes down-regulated by 
bioactive compounds (DCUB), and 1875 bioactive compounds by comparing MAGs 
down-regulated in disease samples and gens up-regulated by bioactive compounds 
(UCDB). We found a total (DCUB + UCDB) of 510 FDA-approved drug candidates for 
repositioning to breast cancer.  
2.2.2.2 Prostate cancer  
We detected 2500 (DCUB), and 1668 bioactive compounds (UCDB) for prostate cancer 
and a total of 484 candidates for repositioning 
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Table 1. Breast cancer and prostate cancer repositioned drug candidates identified 
from analysis of LINCS. Complete lists of repositioned drug candidates for breast 
cancer and prostate cancer are shown in Appendix A. 
 
2.2.3 Supporting evidence 
(1) Sensitivity and specificity 
To evaluate the predictability of the ranked drug candidates, ROC curves were generated 
using 20 FDA breast cancer drugs and 11 FDA prostate cancer drugs as true positive. The 
Breast	Cancer Prostate	Cancer
Total	compounds	 3678 4228
Compounds	that	are	FDA	
drugs
632 676
Compounds	that	are	FDA	
drugs	for	target	disease
20 11
Compounds	that	are	clinical	
drugs	for	target	disease
154 106
UCDB DCUB UCDB DCUB
Compounds	with	FDR	<	
0.05
2435 1875 2500 1668
Compounds	that	are	FDA	
drugs	for	target	disease	
with
FDR	<	0.05	
(p-value)
131	
(6.2E-8)
109	
(2.7E-7)
82	
(4.9E-5)
67	
(4.8E-7)
FDA	drugs	with	FDR	<	0.05 427 325 456 317
FDA	drugs	with	FDR	<	0.05	
in	both	UCDB	and	DCUB

244 291
FDA	drugs	for	target	
disease	with	FDR	<	0.05	
(p-value)
20	
(2.5E-4)
19	
(2.7E-5)
10	
(2.6E-2)
9	
(5.3E-3)
AUC	(p-value) 0.86	(<1.0E-6) 0.81	(<1.0E-6) 0.77		
(9E-3)
0.83	(4.7E-5)
Number	of		
MAG/DRG
237/700 75/100 333/100 46/100
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highest AUC scores were 0.86 (p=1.0E-6) and 0.83 (p=4.5E-5) for breast cancer and 
prostate cancer, respectively. We estimated the significance of the AUC scores by 
randomly selecting 20 out of 3678 compounds for breast cancer and 11 out of 4228 for 
prostate cancer as true positives, and repeating 100,000 times to generate a null 
distribution.  
2.2.4 Comparison with computational drug repositioning methods 
We compared the predictability of our method with that of the computational drug 
repositioning methods, which screen drugs based on the anti-correlation between similar 
gene and disease signatures, omitting the functional correlation between genes. In order 
to compare the performance with Shegimizu et al. [18], and CMap [16], we obtained the 
expression data of 1251, 1079 and 1182 compounds treated in MCF7, HL60 and PC3 
from CMap data sets. We used methods to generate ranked drug lists and compared the 
highest AUC scores. As shown in Fig 2 MFM consistently outperforms the 2 pervious 
methods, sometimes by wide margins.   
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Figure 2. Comparison of performance of the MFM with other methods 
The sensitivity and specificity were calculated as explained in the Methods section, and 
the area under the ROC curve was used as a measure of performance. UCDB: prediction 
of drug candidates that can down-regulate genes up-regulated in cancer. DCUB: 
prediction of drug candidates that can up-regulate genes down-regulated in cancer 
 
(2) Recall rate 
Among 2587 bioactive compounds with FDR less than 0.05, 20/20 (p=2.5E-4) FDA 
breast cancer drugs and 150/173 (p=3.1E-10) clinical drugs (compounds that have been 
in clinical trials for breast cancer) were recalled. For prostate cancer, among 1668 
bioactive compounds with FDR less than 0.05, 10/11 (p=2.6E-2) FDA prostate cancer 
drugs and 89/113 (p=6.3E-6) clinical drugs were recalled. Significance was calculated 
using the Fisher exact test.  
2.2.5 Functional plausibility  
Breast Cancer 
0.9	 0.7	 0.85	 0.94	 0.8	 0.76	0.81	 0.65	 0.67	 0.58	 0.63	 0.6	0.62	 0.58	 0.66	
UCDB	 DCUB	 UCDB	 DCUB	 UCDB	 DCUB	Breast	Cancer	 Leukemia	 Prostate	Cancer	
AUC MFM	 Shegemizu	et	al.	 Lamb	et	al.	
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One way to characterize the functional implications of breast cancer MAGs is     by 
estimating the chance probability of their observed distribution over KEGG pathways. 
We took the MAGs (MAG-UP, see, Appendix B) that produced the drug ranked lists with 
the highest AUC scores after optimization. The MAGs contain 40 breast cancer 
mutations and their 234 filtered first nearest neighbors on the FLN, which are up 
regulated in breast cancer.  
As shown in Appendix B, we found 95 pathways over-represented in breast cancer (FDR 
< 0.05), 18 of which are classified in KEGG as cancer pathways (22 of the 287 KEGG 
pathways, are labeled cancer-related). For example, [24] found that the spliceosome 
assembly pathway is enriched in genes that are overexpressed in breast cancer samples, 
compared to benign lesions. They have shown that siRNA-mediated depletion of SmE 
(SNRPE) or SmD1 (SNRPD1) led to a marked reduction of cell viability in breast cancer 
cell lines, whereas it had little effect on the survival of the nonmalignant MCF10A breast 
epithelial cells [25].  
In addition, signaling pathways that regulate pluripotent stems cells are enriched in 
overexpressed genes that are in the functional neighborhood of genes mutated in breast 
cancer tissue (MAGs, p=4E-09). The deregulation of these pathways many play a role in 
the development of chemoresistance of cancer stem cells, including breast cancer [26]. 
Other published breast cancer causal pathways such as Estrogen signaling [27], ErbB 
[28], neurotrophin [29], MAPK [30] and PI3K/AKT  [31] were significantly enriched in 
mutation associated genes (MAGs). 
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Prostate cancer 
A similar approach was followed for prostate cancer. As summarized in Appendix B, we 
found 117 enriched pathways (FDR <0.05), 18 of which are KEGG cancer pathways, 
including the prostate cancer pathway (p=6.9E-10). There was also supporting evidence 
that showed deregulation of the enriched pathways in prostate cancer. For example, T cell 
infiltration of the prostate induced by androgen withdrawal has been found in patients 
with prostate cancer [32]; the androgen-androgen receptor (AR) system plays vital roles 
in prostate cancer development and progression [33]. Insulin-like growth factor 1 or 
insulin signaling has been found to activate androgen signaling through direct 
interactions of Foxo1 with androgen receptors. Intervention of IGF1/insulin-
phosphatidylinositol 3-kinase-Akt signaling was reported to be of clinical value for 
prostate cancer. T cell receptor, PI3K-Akt, FoxO, and insulin signaling pathways were 
highly ranked candidates with p < E-05. 
 
A number of studies have shown that breast and prostate cancer are genetically related 
[34, 35], as are almost all cancers to various degrees, Our finding that breast and prostate 
cancer share 80 pathways is a striking illustration of this connection (see Appendix B). 
We expect that the selected drug candidates having a strong functional relation (mutual 
predictability score) with this set of genes could potentially correct these aberrant 
functions.  
 
MFM provides functional insight  
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We compared the functional information gained from MAGs with information obtained 
using disease differentially expressed genes (DEGs) (often referred to as disease 
signature genes) exclusively [15, 16]. As shown in Appendix B, we found that our 
current method identifies more significantly enriched pathways and well-documented 
breast cancer and prostate cancer pathways than does the use of differential expression 
alone. To make a comparison, we mapped DEGs onto KEGG pathways. For breast 
cancer, one set contains the most up-regulated 247 DEGs; for prostate cancer, there were 
333 up-regulated DEGs. The disease DEGs were generated from the expression data as 
explained in 2.1.2.1.2 Transcript Level. These results taken collectively suggest that the 
inclusion of mutational and functional information into disease gene signatures, 
substantially improves prediction of disease mechanism and adds specificity and 
accuracy to the identification of repositioned candidates.  
2.2.6 Experimental validation 
Repositioned drug candidates inhibit metabolism of breast cancer cells  
We employed an MTT assay to assess cancer cell viability after drug treatments [36]. In 
particular we tested the viability of 2 breast cancer cell lines:  MCF7 (Luminal A 
subtype), and SUM 149 (Triple negative, inflammatory breast cancer subtype). We 
assessed non specific drug toxicity by comparing the inhibition with that obtained against 
the immortalized but non-malignant MCF10A cell line. 
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We selected for experimental validation 5 FDA-approved drugs with p-value less than 
0.02, and which have not been in clinical trials for breast cancer (Table 2). Doxorubicin, 
a commonly used FDA-approved breast cancer drug, was tested for comparison. 
As shown in Appendix C, MCF7, SUM149 and MCF10A cells exposed to increasing 
concentrations of drugs for 24 hours exhibited a dose dependent reduction in viability. 
The important measure of efficacy is therapeutic index (TI), the IC50 of a drug when it 
targets a non-tumor cell line, relative to its IC50 when it targets a tumor cell line. As 
shown in Figure 3, the TIs of candidates tested against MCF7 and SUM149 are all 
substantially higher than that of Doxorubicin. In addition, all drug candidates except for 
Triprolidine achieved maximum efficacy (Emax) at lower concentrations than did 
Doxorubicin.  
 
FDA Drug *MP score P-value FDR 
Clotrimazole 0.7 5.00E-06 4.88E-05 
Triprolidine 0.69 2.00E-05 1.64E-04 
Thioridazine 0.69 2.00E-05 1.64E-04 
Mefloquine 0.69 3.00E-05 2.28E-04 
Fluphenazine 0.66 1.11E-02 2.13E-02 
 
Table 2 *Mutual predictability score of breast cancer drug candidates predicted by 
MFM 
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FDA	drug	 Doxorubicin	 Clotrimazole	 Triprolidine	 Thioridazine	 Mefloquine	 Fluphenazine	
FDA	approved	
indica/on	
Various	cancers	
including	breast	
cancer	
Fungal	
infec/on	 Rhini/s	
Schizophrenia	
and	generalized	
anxiety	disorder	
Acute	malaria	 Psycho/c	disorders	
 
		(	)		

12	 32	
540	
34	
10	
33	
2	 8	
600	
16	 8	 14	0.8	
34	
850	
36	 20	 37	
*Doxorubicin	 Clotrimazole	 Triprolidine	 Thioridazine	 MeKloquine	 Fluphenazine	
(B)	Half	maximal	inhibitory	
concentration	(IC50) IC50	in	MCF-7	(μM)	 IC50	in	SUM149	(μM)	 IC50	in	MCF10A		(μM)	
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Figure 3. Experimental validation of identified drug candidates for breast cancer 
(A) FDA approved indications of predicted drug candidates; (B) Half maximal inhibitory 
concentration (IC50) (µM) of predicted drug candidates and Doxorubicin against MCF7, 
0.07	
1.06	 1.57	 1.06	
2	
1.12	
0.4	
4.25	
1.42	
2.25	 2.5	 2.64	
*Doxorubicin	Clotrimazole	 Triprolidine	 Thioridazine	 Mefloquine	 Fluphenazine	
(C)	Therapeutic	index	(TI) TI	(MCF7)	 TI	(SUM149)	
>200	
60	
>	1000	
60	
25	
50	
>200	
25	
>1000	
25	 25	
32	
*Doxorubicin	Clotrimazole	 Triprolidine	 Thioridazine	 Mefloquine	 Fluphenazine	
(D)	Maximal	inhibitory	concentra4on	
(Emax) 
Emax	(MCF7)	 Emax	(SUM149)	
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SUM149 and MCF10A; (C) and (D) Therapeutic index (TI) and maximal inhibitory 
concentrations (Emax) of predicted repositioned drug candidates on MCF7, SUM149 and 
MCF10A. (*Currently used drug for breast cancer; Therapeutic index (TI) was calculated 
as a ratio of the IC50 of MCF10A, to the IC50 of MCF7 and SUM149) 
 
2.3 Discussion 
We developed a computational drug screening method -- based on the correlation 
between functional modules of genes perturbed by diseases and drugs -- that could 
potentially accelerate the introduction of new therapeutics for serious diseases and 
conditions. Our approach performed substantially better than previous methods by 
computational measures, and successfully predicted novel drugs that had higher 
inhibitory effect against breast cancer in vitro than Doxorubicin. The study benefited 
substantially from LINCS, the most up to date drug response expression data sets 
currently available. 
 
A number of computational drug-repositioning methods that utilized CMap have been 
devised and the efficacy of identified drugs have been supported by in vivo [12, 15] 
experiments. However, the methodologies are exclusively based on gene expression, 
without taking disease driver/mutated genes or functional information between genes into 
account. [15] Searched for drug candidates based on similarities between drug response 
gene signatures (DEG) and [12] predicted drug molecular functions based on drug 
response gene signatures.  
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Here we indicate a method that has taken this into account and shows better performance 
than previous methods that utilized solely DEGs. We also showed that there was more 
functional information gained from MAGs than significantly differentially expressed 
genes (DEGs). Therefore, we believe that the method could screen more effective 
therapeutics than previous methods. 
 
Of the five drugs for which we did preliminary in vitro tests, they all have higher TI in 
both cell types than does Doxorubicin. Mefloquine is a lipophilic molecule that is an 
FDA-approved anti-malaria agent. It has 3 known protein targets: Fe(II)-protoporphyrin 
IX, hemoglobin subunit alpha, and A2A adenosine receptor (A2AR). Its antimalarial 
action is believed to result from inhibition of heme polymerization within the food 
vacuole in the blood stages of the malaria life cycle [37]. Its potential role as a cancer 
therapeutic; however, stems from its antagonistic action on A2AR [38].  
A study has shown that antagonizing A2AR could provide a basis for cancer 
immunotherapy [39]. Preclinical studies have confirmed that blockade of A2a receptor 
activation has the ability to markedly enhance anti-tumor immunity and be effective 
against melanoma and lymphoma [40-42]. 
 
Tumors may evade immune repose by usurping pathways; such as adenosinergic 
signaling pathway, that negatively regulates immune response. Tumors and its 
microenvironment have been found to have high levels of adenosine and ATP, which is 
triggered by increased cellular turnover and hypoxia [39]. The extracellular adenosine 
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then activates specific purinergic receptors such as A2AR. The activation of A2AR in 
cancer results in inhibition of the immune response to tumors via suppression of T 
regulatory cell function and inhibition of natural killer cell cytotoxicity and tumor-
specific CD4+ and CD8+ T cell activity, therefore, inhibition of A2AR by specific 
antagonists may enhance anti-tumor immunity. 
 
Immunosuppression is associated with hypoxia and accelerated cell turn over. In 
accordance with the findings, in our analysis of pathway enrichment of MAGs for breast 
cancer, cell cycle, HIF1 and T cell signaling pathways were significantly dysregulated in 
breast cancer. Therefore, Mefloquine, the A2aR antagonist could be applied as an 
effective immunotherapeutic strategy. 
 
Fluphenazine and Thioridazine are both antipsychotics. The mechanism of action of 
fluphenazine is not well established, but it is known to antagonize dopamine by binding 
to the D2 receptor. Thioridazine binds a range of receptor types including dopamine and 
various serotonin receptor subtypes. The relationship to inhibition of transformed (MCF7 
and SUM149) cells is not entirely obvious.  
 
In our in vitro study, breast cancer cells had shown resistance against Doxorubicin 
(Emax > 200µM) but the predicted drug candidates including Fluphenazine and 
Thioridazine. The study [43] has found that Thioridazine antagonized dopamine receptors, 
which are expressed on cancer stem cells (CSC) and breast cancer cells, and could induce 
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death of leukemia cancer stem cells preferentially without harming normal blood stem 
cells. The dopamine receptor pathway is known to regulate the growth of CSCs [44]. 
Therefore, Fluphnazine and Thioridazine could inhibit drug resistance of breast cancers 
by modulating CSC through dopamine receptor signaling pathway. 
 
 
2.4 Conclusion 
MFM, which utilizes a functional-linkage network, known mutations, and altered RNA 
levels, appears to be a promising method for identifying multi-targeted drug candidates 
that can correct aberrant cellular functions. In particular the computational performance 
exceeded that of other CMap-based methods, and in vitro experiments indicate that 5/5 
candidates have therapeutic indices superior to that of Doxorubicin in MCF7 and 
SUM149 cancer cell lines. This new approach has the potential to provide a more 
efficient drug discovery pipeline. 
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Appendix A 
 
Rank Drug Name cell MP Score p-value FDR 
1 dactinomycin MCF7 7.42E-01 5.00E-06 4.88E-05 
2 mitoxantrone MCF7 7.38E-01 5.00E-06 4.88E-05 
3 pitavastatin MCF7 7.32E-01 5.00E-06 4.88E-05 
4 teniposide MCF7 7.31E-01 5.00E-06 4.88E-05 
5 piroxicam MCF7 7.30E-01 5.00E-06 4.88E-05 
6 daunorubicin MCF7 7.30E-01 5.00E-06 4.88E-05 
7 5-iodotubercidin MCF7 7.28E-01 5.00E-06 4.88E-05 
8 amsacrine MCF7 7.27E-01 5.00E-06 4.88E-05 
9 idarubicin MCF7 7.26E-01 5.00E-06 4.88E-05 
10 mevastatin MCF7 7.21E-01 5.00E-06 4.88E-05 
11 radicicol MCF7 7.20E-01 5.00E-06 4.88E-05 
12 floxuridine MCF7 7.17E-01 5.00E-06 4.88E-05 
13 cladribine MCF7 7.15E-01 5.00E-06 4.88E-05 
14 disulfiram MCF7 7.13E-01 5.00E-06 4.88E-05 
15 alfuzosin MCF7 7.12E-01 5.00E-06 4.88E-05 
16 fluvastatin MCF7 7.11E-01 5.00E-06 4.88E-05 
17 ivermectin MCF7 7.11E-01 5.00E-06 4.88E-05 
18 resveratrol MCF7 7.10E-01 5.00E-06 4.88E-05 
19 staurosporine MCF7 7.08E-01 5.00E-06 4.88E-05 
20 zafirlukast MCF7 7.05E-01 5.00E-06 4.88E-05 
21 amonafide MCF7 7.05E-01 5.00E-06 4.88E-05 
22 terfenadine MCF7 7.05E-01 5.00E-06 4.88E-05 
23 flurbiprofen MCF7 7.04E-01 5.00E-06 4.88E-05 
24 niacin MCF7 7.03E-01 5.00E-06 4.88E-05 
25 disopyramide MCF7 7.03E-01 5.00E-06 4.88E-05 
26 mebendazole MCF7 7.03E-01 5.00E-06 4.88E-05 
27 lobeline MCF7 7.02E-01 5.00E-06 4.88E-05 
28 clotrimazole MCF7 7.00E-01 5.00E-06 4.88E-05 
29 paroxetine MCF7 6.99E-01 5.00E-06 4.88E-05 
30 aripiprazole MCF7 6.99E-01 5.00E-06 4.88E-05 
31 perhexiline MCF7 6.98E-01 5.00E-06 4.88E-05 
32 brompheniramine MCF7 6.98E-01 5.00E-06 4.88E-05 
33 hyperforin MCF7 6.97E-01 5.00E-06 4.88E-05 
34 fluspirilene MCF7 6.97E-01 5.00E-06 4.88E-05 
35 mesalazine MCF7 6.97E-01 5.00E-06 4.88E-05 
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36 loteprednol MCF7 6.97E-01 5.00E-06 4.88E-05 
37 diltiazem MCF7 6.96E-01 5.00E-06 4.88E-05 
38 px-12 MCF7 6.95E-01 5.00E-06 4.88E-05 
39 terbutaline MCF7 6.95E-01 5.00E-06 4.88E-05 
40 rifabutin MCF7 6.94E-01 5.00E-06 4.88E-05 
41 methantheline MCF7 6.93E-01 5.00E-06 4.88E-05 
42 trazodone MCF7 6.93E-01 5.00E-06 4.88E-05 
43 alitretinoin MCF7 6.92E-01 5.00E-06 4.88E-05 
44 triclosan MCF7 6.92E-01 5.00E-06 4.88E-05 
45 miconazole MCF7 6.92E-01 5.00E-06 4.88E-05 
46 valdecoxib MCF7 6.91E-01 5.00E-06 4.88E-05 
47 maprotiline MCF7 6.91E-01 5.00E-06 4.88E-05 
48 trifluoperazine MCF7 6.91E-01 5.00E-06 4.88E-05 
49 raltitrexed MCF7 6.91E-01 5.00E-06 4.88E-05 
50 ciclopirox MCF7 6.91E-01 1.00E-05 8.95E-05 
51 mercaptopurine MCF7 6.91E-01 1.00E-05 8.95E-05 
52 cerivastatin MCF7 6.91E-01 1.00E-05 8.95E-05 
53 quercetin MCF7 6.90E-01 1.00E-05 8.95E-05 
54 flutamide MCF7 6.90E-01 1.00E-05 8.95E-05 
55 chloramphenicol MCF7 6.90E-01 1.00E-05 8.95E-05 
56 triprolidine MCF7 6.88E-01 2.00E-05 1.64E-04 
57 protriptyline MCF7 6.88E-01 2.00E-05 1.64E-04 
58 thioridazine MCF7 6.88E-01 2.00E-05 1.64E-04 
59 betamethasone MCF7 6.88E-01 2.00E-05 1.64E-04 
60 sertindole MCF7 6.88E-01 2.00E-05 1.64E-04 
61 mefloquine MCF7 6.87E-01 3.00E-05 2.28E-04 
62 tyloxapol MCF7 6.87E-01 3.00E-05 2.28E-04 
63 forskolin MCF7 6.87E-01 3.00E-05 2.28E-04 
64 cytarabine MCF7 6.86E-01 3.00E-05 2.28E-04 
65 nitazoxanide MCF7 6.86E-01 4.00E-05 2.81E-04 
66 norfloxacin MCF7 6.86E-01 4.00E-05 2.81E-04 
67 tioconazole MCF7 6.85E-01 4.00E-05 2.81E-04 
68 thiethylperazine MCF7 6.85E-01 4.00E-05 2.81E-04 
69 auranofin MCF7 6.85E-01 5.00E-05 3.21E-04 
70 fluoxetine MCF7 6.84E-01 5.00E-05 3.21E-04 
71 rifampicin MCF7 6.84E-01 5.00E-05 3.21E-04 
72 azathioprine MCF7 6.83E-01 5.00E-05 3.21E-04 
73 fludrocortisone MCF7 6.83E-01 5.00E-05 3.21E-04 
74 imipramine MCF7 6.83E-01 5.00E-05 3.21E-04 
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75 nilotinib MCF7 6.83E-01 7.00E-05 4.47E-04 
76 torasemide MCF7 6.83E-01 9.00E-05 5.47E-04 
77 myricetin MCF7 6.83E-01 9.00E-05 5.47E-04 
78 azd-8330 MCF7 6.82E-01 1.00E-04 5.99E-04 
79 bromocriptine MCF7 6.82E-01 1.00E-04 5.99E-04 
80 itopride MCF7 6.82E-01 1.10E-04 6.40E-04 
81 vx-702 MCF7 6.82E-01 1.10E-04 6.40E-04 
82 dantrolene MCF7 6.82E-01 1.10E-04 6.40E-04 
83 finasteride MCF7 6.81E-01 1.10E-04 6.40E-04 
84 terazosin MCF7 6.81E-01 1.20E-04 6.78E-04 
85 rofecoxib MCF7 6.81E-01 1.30E-04 7.30E-04 
86 levetiracetam MCF7 6.81E-01 1.50E-04 8.32E-04 
87 pentamidine MCF7 6.80E-01 1.80E-04 9.88E-04 
88 minoxidil MCF7 6.80E-01 1.90E-04 1.02E-03 
89 losartan MCF7 6.80E-01 1.90E-04 1.02E-03 
90 procainamide MCF7 6.80E-01 1.90E-04 1.02E-03 
91 indapamide MCF7 6.80E-01 2.10E-04 1.13E-03 
92 nicotinamide MCF7 6.80E-01 2.50E-04 1.32E-03 
93 clomifene MCF7 6.79E-01 2.90E-04 1.51E-03 
94 desloratadine MCF7 6.79E-01 3.00E-04 1.56E-03 
95 zileuton MCF7 6.79E-01 3.20E-04 1.61E-03 
96 astemizole MCF7 6.79E-01 3.20E-04 1.61E-03 
97 midodrine MCF7 6.79E-01 3.20E-04 1.61E-03 
98 nateglinide MCF7 6.79E-01 3.30E-04 1.65E-03 
99 donepezil MCF7 6.79E-01 3.30E-04 1.65E-03 
100 geldanamycin MCF7 6.78E-01 3.70E-04 1.83E-03 
101 monobenzone MCF7 6.78E-01 4.10E-04 1.98E-03 
102 gemfibrozil MCF7 6.78E-01 4.30E-04 2.06E-03 
103 acebutolol MCF7 6.78E-01 4.70E-04 2.21E-03 
104 colchicine MCF7 6.77E-01 4.70E-04 2.21E-03 
105 amisulpride MCF7 6.77E-01 4.70E-04 2.21E-03 
106 isradipine MCF7 6.77E-01 4.70E-04 2.21E-03 
107 homoharringtonin
e 
MCF7 6.77E-01 5.30E-04 2.41E-03 
108 pyrimethamine MCF7 6.77E-01 5.30E-04 2.41E-03 
109 atracurium MCF7 6.77E-01 5.30E-04 2.41E-03 
110 chlormezanone MCF7 6.77E-01 5.50E-04 2.43E-03 
111 mitotane MCF7 6.77E-01 5.50E-04 2.43E-03 
112 propidium MCF7 6.77E-01 5.50E-04 2.43E-03 
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113 medrysone MCF7 6.77E-01 5.50E-04 2.43E-03 
114 amlodipine MCF7 6.77E-01 5.50E-04 2.43E-03 
115 benzonatate MCF7 6.76E-01 5.50E-04 2.43E-03 
116 chlorphenamine MCF7 6.76E-01 5.50E-04 2.43E-03 
117 estropipate MCF7 6.76E-01 5.60E-04 2.45E-03 
118 valsartan MCF7 6.76E-01 5.80E-04 2.53E-03 
119 triamcinolone MCF7 6.76E-01 5.90E-04 2.56E-03 
120 glipizide MCF7 6.76E-01 5.90E-04 2.56E-03 
121 dofetilide MCF7 6.76E-01 5.90E-04 2.56E-03 
122 olopatadine MCF7 6.76E-01 5.90E-04 2.56E-03 
123 moclobemide MCF7 6.76E-01 5.90E-04 2.56E-03 
124 granisetron MCF7 6.76E-01 6.10E-04 2.63E-03 
125 liothyronine MCF7 6.76E-01 6.20E-04 2.64E-03 
126 ethotoin MCF7 6.76E-01 6.20E-04 2.64E-03 
127 etodolac MCF7 6.76E-01 6.20E-04 2.64E-03 
128 oxybuprocaine MCF7 6.75E-01 6.50E-04 2.75E-03 
129 pimozide MCF7 6.75E-01 6.50E-04 2.75E-03 
130 propantheline MCF7 6.75E-01 6.60E-04 2.78E-03 
131 prednicarbate MCF7 6.75E-01 6.70E-04 2.81E-03 
132 nalbuphine MCF7 6.75E-01 6.70E-04 2.81E-03 
133 norgestimate MCF7 6.75E-01 6.80E-04 2.84E-03 
134 hydroflumethiazid
e 
MCF7 6.75E-01 6.80E-04 2.84E-03 
135 genistein MCF7 6.75E-01 7.00E-04 2.90E-03 
136 nabumetone MCF7 6.75E-01 7.60E-04 3.11E-03 
137 cisapride MCF7 6.75E-01 7.80E-04 3.17E-03 
138 tridihexethyl MCF7 6.74E-01 8.10E-04 3.26E-03 
139 mometasone MCF7 6.74E-01 8.40E-04 3.33E-03 
140 nisoldipine MCF7 6.74E-01 8.40E-04 3.33E-03 
141 methylergometrin
e 
MCF7 6.74E-01 8.60E-04 3.39E-03 
142 olmesartan MCF7 6.74E-01 9.00E-04 3.48E-03 
143 fluocinonide MCF7 6.74E-01 9.00E-04 3.48E-03 
144 warfarin MCF7 6.74E-01 9.40E-04 3.59E-03 
145 practolol MCF7 6.74E-01 9.60E-04 3.64E-03 
146 rivaroxaban MCF7 6.73E-01 1.00E-03 3.76E-03 
147 rizatriptan MCF7 6.73E-01 1.00E-03 3.76E-03 
148 vardenafil MCF7 6.73E-01 1.04E-03 3.89E-03 
149 nialamide MCF7 6.73E-01 1.05E-03 3.92E-03 
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150 tretinoin MCF7 6.73E-01 1.05E-03 3.92E-03 
151 carbinoxamine MCF7 6.73E-01 1.07E-03 3.97E-03 
152 pirenzepine MCF7 6.73E-01 1.07E-03 3.97E-03 
153 tofacitinib MCF7 6.73E-01 1.09E-03 4.03E-03 
154 huperzine-a MCF7 6.73E-01 1.11E-03 4.09E-03 
155 tolterodine MCF7 6.73E-01 1.13E-03 4.14E-03 
156 griseofulvin MCF7 6.73E-01 1.13E-03 4.14E-03 
157 phenoxybenzamin
e 
MCF7 6.73E-01 1.15E-03 4.19E-03 
158 perphenazine MCF7 6.73E-01 1.23E-03 4.39E-03 
159 ponatinib MCF7 6.73E-01 1.23E-03 4.39E-03 
160 clopidogrel MCF7 6.73E-01 1.23E-03 4.39E-03 
161 hydrocortisone MCF7 6.73E-01 1.24E-03 4.39E-03 
162 zimelidine MCF7 6.72E-01 1.24E-03 4.39E-03 
163 tolazamide MCF7 6.72E-01 1.24E-03 4.39E-03 
164 betaxolol MCF7 6.72E-01 1.24E-03 4.39E-03 
165 amperozide MCF7 6.72E-01 1.27E-03 4.45E-03 
166 amoxapine MCF7 6.72E-01 1.27E-03 4.45E-03 
167 clomipramine MCF7 6.72E-01 1.29E-03 4.48E-03 
168 glycopyrrolate MCF7 6.72E-01 1.32E-03 4.57E-03 
169 cilostazol MCF7 6.72E-01 1.33E-03 4.59E-03 
170 biotin MCF7 6.72E-01 1.36E-03 4.64E-03 
171 prazosin MCF7 6.72E-01 1.36E-03 4.64E-03 
172 tropicamide MCF7 6.72E-01 1.36E-03 4.64E-03 
173 quetiapine MCF7 6.72E-01 1.38E-03 4.69E-03 
174 parecoxib MCF7 6.72E-01 1.39E-03 4.71E-03 
175 atomoxetine MCF7 6.72E-01 1.39E-03 4.71E-03 
176 albendazole MCF7 6.72E-01 1.42E-03 4.77E-03 
177 etomidate MCF7 6.72E-01 1.49E-03 4.96E-03 
178 probenecid MCF7 6.71E-01 1.55E-03 5.13E-03 
179 escitalopram MCF7 6.71E-01 1.55E-03 5.13E-03 
180 scopolamine MCF7 6.71E-01 1.59E-03 5.24E-03 
181 diflunisal MCF7 6.71E-01 1.61E-03 5.27E-03 
182 ezetimibe MCF7 6.71E-01 1.65E-03 5.39E-03 
183 epinephrine MCF7 6.71E-01 1.67E-03 5.45E-03 
184 dydrogesterone MCF7 6.71E-01 1.70E-03 5.48E-03 
185 dexfenfluramine MCF7 6.71E-01 1.70E-03 5.48E-03 
186 oxprenolol MCF7 6.71E-01 1.71E-03 5.50E-03 
187 guanabenz MCF7 6.71E-01 1.75E-03 5.62E-03 
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188 sparfloxacin MCF7 6.70E-01 1.78E-03 5.67E-03 
189 riboflavin MCF7 6.70E-01 1.82E-03 5.80E-03 
190 desipramine MCF7 6.70E-01 1.88E-03 5.96E-03 
191 metamizole MCF7 6.70E-01 1.90E-03 6.01E-03 
192 nocodazole MCF7 6.70E-01 1.96E-03 6.16E-03 
193 pravastatin MCF7 6.70E-01 1.98E-03 6.17E-03 
194 edrophonium MCF7 6.70E-01 1.98E-03 6.17E-03 
195 gentamicin MCF7 6.70E-01 2.02E-03 6.24E-03 
196 levocabastine MCF7 6.70E-01 2.03E-03 6.24E-03 
197 labetalol MCF7 6.70E-01 2.03E-03 6.24E-03 
198 methazolamide MCF7 6.70E-01 2.04E-03 6.24E-03 
199 telmisartan MCF7 6.70E-01 2.04E-03 6.24E-03 
200 thiothixene MCF7 6.70E-01 2.04E-03 6.24E-03 
201 prenylamine MCF7 6.70E-01 2.05E-03 6.25E-03 
202 alimemazine MCF7 6.70E-01 2.28E-03 6.84E-03 
203 dienestrol MCF7 6.69E-01 2.32E-03 6.95E-03 
204 desoximetasone MCF7 6.69E-01 2.44E-03 7.21E-03 
205 ethynodiol MCF7 6.69E-01 2.45E-03 7.23E-03 
206 didanosine MCF7 6.69E-01 2.47E-03 7.28E-03 
207 pentolinium MCF7 6.69E-01 2.49E-03 7.32E-03 
208 tiagabine MCF7 6.69E-01 2.54E-03 7.43E-03 
209 zolmitriptan MCF7 6.69E-01 2.54E-03 7.43E-03 
210 repaglinide MCF7 6.69E-01 2.57E-03 7.49E-03 
211 doxepin MCF7 6.69E-01 2.57E-03 7.49E-03 
212 pregnenolone MCF7 6.69E-01 2.62E-03 7.59E-03 
213 orciprenaline MCF7 6.69E-01 2.72E-03 7.76E-03 
214 tocainide MCF7 6.69E-01 2.77E-03 7.88E-03 
215 naloxone MCF7 6.69E-01 2.87E-03 8.13E-03 
216 orphenadrine MCF7 6.68E-01 2.96E-03 8.27E-03 
217 chlorpromazine MCF7 6.68E-01 3.04E-03 8.41E-03 
218 isotretinoin MCF7 6.68E-01 3.04E-03 8.41E-03 
219 furosemide MCF7 6.68E-01 3.19E-03 8.61E-03 
220 carbidopa MCF7 6.68E-01 3.22E-03 8.61E-03 
221 sulfasalazine MCF7 6.68E-01 3.22E-03 8.61E-03 
222 tolmetin MCF7 6.68E-01 3.22E-03 8.61E-03 
223 vincristine MCF7 6.68E-01 3.22E-03 8.61E-03 
224 dyclonine MCF7 6.68E-01 3.23E-03 8.61E-03 
225 lansoprazole MCF7 6.68E-01 3.23E-03 8.61E-03 
226 mepivacaine MCF7 6.68E-01 3.24E-03 8.61E-03 
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227 ranolazine MCF7 6.68E-01 3.24E-03 8.61E-03 
228 fluorometholone MCF7 6.68E-01 3.31E-03 8.75E-03 
229 diphenylpyraline MCF7 6.68E-01 3.31E-03 8.75E-03 
230 acetazolamide MCF7 6.67E-01 3.36E-03 8.85E-03 
231 equilin MCF7 6.67E-01 3.37E-03 8.85E-03 
232 amodiaquine MCF7 6.67E-01 3.39E-03 8.87E-03 
233 probucol MCF7 6.67E-01 3.49E-03 9.10E-03 
234 propafenone MCF7 6.67E-01 3.53E-03 9.16E-03 
235 atovaquone MCF7 6.67E-01 3.54E-03 9.18E-03 
236 mestranol MCF7 6.67E-01 3.66E-03 9.41E-03 
237 nimodipine MCF7 6.67E-01 3.66E-03 9.41E-03 
238 oxybutynin MCF7 6.67E-01 3.70E-03 9.48E-03 
239 isoprenaline MCF7 6.67E-01 3.72E-03 9.49E-03 
240 tegaserod MCF7 6.67E-01 3.86E-03 9.77E-03 
241 methyldopa MCF7 6.67E-01 3.90E-03 9.80E-03 
242 acetylcysteine MCF7 6.67E-01 4.00E-03 9.97E-03 
243 metyrapone MCF7 6.66E-01 4.08E-03 1.01E-02 
244 lomefloxacin MCF7 6.66E-01 4.13E-03 1.02E-02 
245 felbamate MCF7 6.66E-01 4.17E-03 1.03E-02 
246 alfacalcidol MCF7 6.66E-01 4.19E-03 1.04E-02 
247 procaine MCF7 6.66E-01 4.21E-03 1.04E-02 
248 trimipramine MCF7 6.66E-01 4.21E-03 1.04E-02 
249 phenytoin MCF7 6.66E-01 4.21E-03 1.04E-02 
250 terbinafine MCF7 6.66E-01 4.21E-03 1.04E-02 
251 tolazoline MCF7 6.66E-01 4.34E-03 1.06E-02 
252 picrotoxin MCF7 6.66E-01 4.41E-03 1.08E-02 
253 citalopram MCF7 6.66E-01 4.47E-03 1.09E-02 
254 danazol MCF7 6.66E-01 4.55E-03 1.10E-02 
255 nicotine MCF7 6.66E-01 4.56E-03 1.10E-02 
256 latanoprost MCF7 6.66E-01 4.67E-03 1.11E-02 
257 rosiglitazone MCF7 6.66E-01 4.68E-03 1.12E-02 
258 metoclopramide MCF7 6.66E-01 4.71E-03 1.12E-02 
259 amiloride MCF7 6.66E-01 4.72E-03 1.12E-02 
260 clocortolone MCF7 6.66E-01 4.75E-03 1.13E-02 
261 antazoline MCF7 6.66E-01 4.80E-03 1.14E-02 
262 amiodarone MCF7 6.66E-01 4.80E-03 1.14E-02 
263 ketorolac MCF7 6.65E-01 4.84E-03 1.14E-02 
264 salmeterol MCF7 6.65E-01 4.91E-03 1.15E-02 
265 bumetanide MCF7 6.65E-01 5.09E-03 1.18E-02 
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266 dopamine MCF7 6.65E-01 5.14E-03 1.19E-02 
267 isometheptene MCF7 6.65E-01 5.19E-03 1.19E-02 
268 chlorzoxazone MCF7 6.65E-01 5.37E-03 1.23E-02 
269 bambuterol MCF7 6.65E-01 5.40E-03 1.23E-02 
270 selegiline MCF7 6.64E-01 5.57E-03 1.26E-02 
271 iloperidone MCF7 6.64E-01 5.63E-03 1.27E-02 
272 bosentan MCF7 6.64E-01 5.64E-03 1.27E-02 
273 rimexolone MCF7 6.64E-01 5.65E-03 1.27E-02 
274 trihexyphenidyl MCF7 6.64E-01 5.67E-03 1.27E-02 
275 droperidol MCF7 6.64E-01 5.76E-03 1.28E-02 
276 metaraminol MCF7 6.64E-01 5.77E-03 1.28E-02 
277 bendroflumethiazi
de 
MCF7 6.64E-01 5.81E-03 1.29E-02 
278 phentermine MCF7 6.64E-01 5.81E-03 1.29E-02 
279 vecuronium MCF7 6.64E-01 5.87E-03 1.30E-02 
280 carbamazepine MCF7 6.64E-01 6.28E-03 1.38E-02 
281 flunisolide MCF7 6.64E-01 6.29E-03 1.38E-02 
282 pentobarbital MCF7 6.64E-01 6.33E-03 1.39E-02 
283 fenoterol MCF7 6.64E-01 6.44E-03 1.41E-02 
284 bacitracin MCF7 6.64E-01 6.44E-03 1.41E-02 
285 azelastine MCF7 6.64E-01 6.44E-03 1.41E-02 
286 vatalanib MCF7 6.64E-01 6.49E-03 1.41E-02 
287 molindone MCF7 6.64E-01 6.68E-03 1.45E-02 
288 galantamine MCF7 6.63E-01 6.69E-03 1.45E-02 
289 enalapril MCF7 6.63E-01 6.70E-03 1.45E-02 
290 nadolol MCF7 6.63E-01 6.76E-03 1.46E-02 
291 oxyphenonium MCF7 6.63E-01 6.83E-03 1.47E-02 
292 sertraline MCF7 6.63E-01 6.95E-03 1.49E-02 
293 epibatidine MCF7 6.63E-01 7.29E-03 1.54E-02 
294 chlordiazepoxide MCF7 6.63E-01 7.29E-03 1.54E-02 
295 carbimazole MCF7 6.63E-01 7.31E-03 1.55E-02 
296 mecamylamine MCF7 6.63E-01 7.42E-03 1.56E-02 
297 penbutolol MCF7 6.63E-01 7.48E-03 1.57E-02 
298 guanethidine MCF7 6.63E-01 7.66E-03 1.60E-02 
299 pancuronium MCF7 6.63E-01 7.74E-03 1.62E-02 
300 flavoxate MCF7 6.63E-01 7.77E-03 1.62E-02 
301 flecainide MCF7 6.63E-01 7.79E-03 1.63E-02 
302 mesoridazine MCF7 6.62E-01 7.88E-03 1.64E-02 
303 tizanidine MCF7 6.62E-01 7.90E-03 1.64E-02 
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304 tramadol MCF7 6.62E-01 7.97E-03 1.65E-02 
305 benzatropine MCF7 6.62E-01 8.00E-03 1.65E-02 
306 troglitazone MCF7 6.62E-01 8.00E-03 1.65E-02 
307 topiramate MCF7 6.62E-01 8.03E-03 1.66E-02 
308 nitrendipine MCF7 6.62E-01 8.82E-03 1.78E-02 
309 alosetron MCF7 6.62E-01 8.84E-03 1.78E-02 
310 carbachol MCF7 6.62E-01 8.86E-03 1.78E-02 
311 doxylamine MCF7 6.62E-01 9.12E-03 1.82E-02 
312 rutin MCF7 6.61E-01 9.39E-03 1.86E-02 
313 ticlopidine MCF7 6.61E-01 9.39E-03 1.86E-02 
314 phenylpropanolam
ine 
MCF7 6.61E-01 9.50E-03 1.88E-02 
315 benzthiazide MCF7 6.61E-01 9.50E-03 1.88E-02 
316 cyproheptadine MCF7 6.61E-01 9.70E-03 1.91E-02 
317 balsalazide MCF7 6.61E-01 9.82E-03 1.93E-02 
318 vemurafenib MCF7 6.61E-01 1.02E-02 1.99E-02 
319 hydroxyfasudil MCF7 6.61E-01 1.02E-02 1.99E-02 
320 metixene MCF7 6.61E-01 1.04E-02 2.01E-02 
321 pilocarpine MCF7 6.61E-01 1.04E-02 2.01E-02 
322 reboxetine MCF7 6.61E-01 1.04E-02 2.02E-02 
323 cefdinir MCF7 6.61E-01 1.09E-02 2.10E-02 
324 fluphenazine MCF7 6.60E-01 1.11E-02 2.13E-02 
325 clenbuterol MCF7 6.60E-01 1.14E-02 2.18E-02 
326 montelukast MCF7 6.60E-01 1.16E-02 2.20E-02 
327 haloperidol MCF7 6.60E-01 1.17E-02 2.23E-02 
328 milnacipran MCF7 6.60E-01 1.18E-02 2.25E-02 
329 sulfinpyrazone MCF7 6.60E-01 1.21E-02 2.28E-02 
330 prilocaine MCF7 6.60E-01 1.21E-02 2.28E-02 
331 nicardipine MCF7 6.60E-01 1.22E-02 2.29E-02 
332 dobutamine MCF7 6.60E-01 1.26E-02 2.35E-02 
333 flunarizine MCF7 6.60E-01 1.27E-02 2.37E-02 
334 tadalafil MCF7 6.60E-01 1.28E-02 2.38E-02 
335 acetylcholine MCF7 6.59E-01 1.30E-02 2.41E-02 
336 carteolol MCF7 6.59E-01 1.35E-02 2.48E-02 
337 phylloquinone MCF7 6.59E-01 1.35E-02 2.48E-02 
338 ribostamycin MCF7 6.59E-01 1.38E-02 2.54E-02 
339 ketotifen MCF7 6.59E-01 1.43E-02 2.61E-02 
340 bupropion MCF7 6.59E-01 1.45E-02 2.64E-02 
341 lamotrigine MCF7 6.59E-01 1.48E-02 2.68E-02 
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342 zuclopenthixol MCF7 6.59E-01 1.51E-02 2.72E-02 
343 doxapram MCF7 6.58E-01 1.55E-02 2.78E-02 
344 aminophylline MCF7 6.58E-01 1.56E-02 2.79E-02 
345 alprenolol MCF7 6.58E-01 1.57E-02 2.80E-02 
346 budesonide MCF7 6.58E-01 1.57E-02 2.81E-02 
347 propylthiouracil MCF7 6.58E-01 1.60E-02 2.85E-02 
348 flupirtine MCF7 6.58E-01 1.61E-02 2.86E-02 
349 flucytosine MCF7 6.58E-01 1.62E-02 2.88E-02 
350 nitrazepam MCF7 6.58E-01 1.64E-02 2.91E-02 
351 sibutramine MCF7 6.58E-01 1.65E-02 2.91E-02 
352 demecarium MCF7 6.58E-01 1.65E-02 2.92E-02 
353 reserpine MCF7 6.58E-01 1.70E-02 2.98E-02 
354 dexbrompheniram
ine 
MCF7 6.58E-01 1.70E-02 2.99E-02 
355 ibudilast MCF7 6.58E-01 1.70E-02 2.99E-02 
356 treprostinil MCF7 6.58E-01 1.71E-02 3.00E-02 
357 acetohexamide MCF7 6.58E-01 1.71E-02 3.01E-02 
358 triflusal MCF7 6.58E-01 1.74E-02 3.04E-02 
359 menadione MCF7 6.58E-01 1.76E-02 3.06E-02 
360 glimepiride MCF7 6.58E-01 1.77E-02 3.07E-02 
361 thioproperazine MCF7 6.57E-01 1.78E-02 3.08E-02 
362 risperidone MCF7 6.57E-01 1.78E-02 3.08E-02 
363 acenocoumarol MCF7 6.57E-01 1.78E-02 3.08E-02 
364 triflupromazine MCF7 6.57E-01 1.78E-02 3.08E-02 
365 papaverine MCF7 6.57E-01 1.87E-02 3.21E-02 
366 hyoscyamine MCF7 6.57E-01 1.87E-02 3.21E-02 
367 clozapine MCF7 6.57E-01 1.87E-02 3.21E-02 
368 phenazopyridine MCF7 6.57E-01 1.88E-02 3.22E-02 
369 diphenidol MCF7 6.57E-01 1.89E-02 3.23E-02 
370 progesterone MCF7 6.57E-01 1.91E-02 3.25E-02 
371 amcinonide MCF7 6.57E-01 1.91E-02 3.26E-02 
372 timolol MCF7 6.57E-01 1.93E-02 3.26E-02 
373 isocarboxazid MCF7 6.57E-01 1.95E-02 3.30E-02 
374 carbetocin MCF7 6.57E-01 1.96E-02 3.32E-02 
375 tripelennamine MCF7 6.57E-01 1.97E-02 3.32E-02 
376 clemastine MCF7 6.57E-01 1.97E-02 3.32E-02 
377 betahistine MCF7 6.57E-01 1.99E-02 3.35E-02 
378 benzocaine MCF7 6.57E-01 2.06E-02 3.44E-02 
379 nicergoline MCF7 6.56E-01 2.11E-02 3.52E-02 
		
40 
380 mafenide MCF7 6.56E-01 2.12E-02 3.54E-02 
381 pindolol MCF7 6.56E-01 2.14E-02 3.55E-02 
382 chlorotrianisene MCF7 6.56E-01 2.15E-02 3.56E-02 
383 irbesartan MCF7 6.56E-01 2.15E-02 3.57E-02 
384 nifedipine MCF7 6.56E-01 2.16E-02 3.58E-02 
385 pioglitazone MCF7 6.56E-01 2.18E-02 3.60E-02 
386 rabeprazole MCF7 6.56E-01 2.23E-02 3.68E-02 
387 zonisamide MCF7 6.56E-01 2.26E-02 3.72E-02 
388 sumatriptan MCF7 6.56E-01 2.31E-02 3.79E-02 
389 oxaprozin MCF7 6.56E-01 2.33E-02 3.81E-02 
390 dextromethorphan MCF7 6.56E-01 2.34E-02 3.82E-02 
391 thiorphan MCF7 6.56E-01 2.37E-02 3.86E-02 
392 pramipexole MCF7 6.56E-01 2.37E-02 3.86E-02 
393 mepyramine MCF7 6.56E-01 2.37E-02 3.86E-02 
394 biperiden MCF7 6.55E-01 2.38E-02 3.87E-02 
395 oxcarbazepine MCF7 6.55E-01 2.43E-02 3.94E-02 
396 palonosetron MCF7 6.55E-01 2.46E-02 3.98E-02 
397 mephenytoin MCF7 6.55E-01 2.47E-02 3.99E-02 
398 thiamine MCF7 6.55E-01 2.52E-02 4.05E-02 
399 physostigmine MCF7 6.55E-01 2.56E-02 4.09E-02 
400 tolbutamide MCF7 6.55E-01 2.60E-02 4.14E-02 
401 icosapent MCF7 6.55E-01 2.61E-02 4.15E-02 
402 procyclidine MCF7 6.55E-01 2.63E-02 4.17E-02 
403 fenoprofen MCF7 6.55E-01 2.63E-02 4.17E-02 
404 zolpidem MCF7 6.55E-01 2.63E-02 4.17E-02 
405 dorzolamide MCF7 6.55E-01 2.63E-02 4.17E-02 
406 famotidine MCF7 6.55E-01 2.64E-02 4.19E-02 
407 dipyridamole MCF7 6.55E-01 2.66E-02 4.20E-02 
408 carprofen MCF7 6.55E-01 2.68E-02 4.23E-02 
409 tetrabenazine MCF7 6.55E-01 2.69E-02 4.24E-02 
410 primaquine MCF7 6.55E-01 2.71E-02 4.28E-02 
411 sitagliptin MCF7 6.54E-01 2.77E-02 4.36E-02 
412 etoricoxib MCF7 6.54E-01 2.87E-02 4.47E-02 
413 fenofibrate MCF7 6.54E-01 2.88E-02 4.49E-02 
414 fexofenadine MCF7 6.54E-01 2.91E-02 4.53E-02 
415 estrone MCF7 6.54E-01 2.97E-02 4.60E-02 
416 triamterene MCF7 6.54E-01 2.98E-02 4.61E-02 
417 enoxacin MCF7 6.54E-01 2.98E-02 4.61E-02 
418 hydroxyzine MCF7 6.54E-01 2.99E-02 4.61E-02 
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419 cyanocobalamin MCF7 6.54E-01 3.00E-02 4.63E-02 
420 alprazolam MCF7 6.54E-01 3.03E-02 4.67E-02 
421 quinidine MCF7 6.54E-01 3.04E-02 4.68E-02 
422 acitretin MCF7 6.54E-01 3.06E-02 4.71E-02 
423 phenelzine MCF7 6.54E-01 3.10E-02 4.77E-02 
424 acamprosate MCF7 6.54E-01 3.11E-02 4.77E-02 
425 norethindrone MCF7 6.53E-01 3.24E-02 4.93E-02 
426 vindesine MCF7 6.53E-01 3.24E-02 4.93E-02 
427 nefazodone MCF7 6.53E-01 3.26E-02 4.94E-02 
428 oxandrolone MCF7 6.53E-01 3.37E-02 5.07E-02 
429 esmolol MCF7 6.53E-01 3.39E-02 5.09E-02 
430 cinchocaine MCF7 6.53E-01 3.52E-02 5.25E-02 
431 remoxipride MCF7 6.53E-01 3.57E-02 5.31E-02 
432 varenicline MCF7 6.52E-01 3.69E-02 5.44E-02 
433 ofloxacin MCF7 6.52E-01 3.70E-02 5.46E-02 
434 chlorothiazide MCF7 6.52E-01 3.72E-02 5.47E-02 
435 cefazolin MCF7 6.52E-01 3.76E-02 5.52E-02 
436 benazepril MCF7 6.52E-01 3.83E-02 5.60E-02 
437 halofantrine MCF7 6.52E-01 3.89E-02 5.67E-02 
438 zidovudine MCF7 6.52E-01 4.00E-02 5.80E-02 
439 mexiletine MCF7 6.51E-01 4.11E-02 5.91E-02 
440 tacrine MCF7 6.51E-01 4.16E-02 5.97E-02 
441 brinzolamide MCF7 6.51E-01 4.16E-02 5.97E-02 
442 olanzapine MCF7 6.51E-01 4.16E-02 5.97E-02 
443 bifonazole MCF7 6.51E-01 4.17E-02 5.97E-02 
444 phenformin MCF7 6.51E-01 4.20E-02 6.01E-02 
445 theophylline MCF7 6.51E-01 4.23E-02 6.04E-02 
446 phenylbutazone MCF7 6.51E-01 4.29E-02 6.10E-02 
447 quinethazone MCF7 6.51E-01 4.35E-02 6.18E-02 
448 ethosuximide MCF7 6.51E-01 4.47E-02 6.33E-02 
449 amlexanox MCF7 6.51E-01 4.49E-02 6.35E-02 
450 ibutilide MCF7 6.51E-01 4.53E-02 6.39E-02 
451 anagrelide MCF7 6.50E-01 4.74E-02 6.65E-02 
452 cinacalcet MCF7 6.50E-01 4.84E-02 6.78E-02 
453 verapamil MCF7 6.50E-01 4.94E-02 6.88E-02 
454 tetracycline MCF7 6.50E-01 5.00E-02 6.96E-02 
455 maraviroc MCF7 6.50E-01 5.01E-02 6.96E-02 
456 amitriptyline MCF7 6.50E-01 5.03E-02 6.98E-02 
457 clofibrate MCF7 6.50E-01 5.08E-02 7.02E-02 
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458 vigabatrin MCF7 6.50E-01 5.16E-02 7.11E-02 
459 cyclizine MCF7 6.49E-01 5.27E-02 7.25E-02 
460 suprofen MCF7 6.49E-01 5.29E-02 7.27E-02 
461 bepridil MCF7 6.49E-01 5.31E-02 7.30E-02 
462 cyclopentolate MCF7 6.49E-01 5.36E-02 7.35E-02 
463 trichlormethiazide MCF7 6.49E-01 5.40E-02 7.38E-02 
464 ketoprofen MCF7 6.49E-01 5.40E-02 7.38E-02 
465 7-nitroindazole MCF7 6.49E-01 5.46E-02 7.45E-02 
466 chlorprothixene MCF7 6.49E-01 5.53E-02 7.53E-02 
467 dihydroergotamin
e 
MCF7 6.49E-01 5.60E-02 7.60E-02 
468 diethylstilbestrol MCF7 6.49E-01 5.66E-02 7.67E-02 
469 mianserin MCF7 6.49E-01 5.69E-02 7.70E-02 
470 minaprine MCF7 6.49E-01 5.70E-02 7.72E-02 
471 atenolol MCF7 6.49E-01 5.74E-02 7.76E-02 
472 miglitol MCF7 6.49E-01 5.74E-02 7.76E-02 
473 phenacetin MCF7 6.49E-01 5.81E-02 7.82E-02 
474 levothyroxine MCF7 6.49E-01 5.81E-02 7.82E-02 
475 bezafibrate MCF7 6.49E-01 5.81E-02 7.82E-02 
476 doxazosin MCF7 6.48E-01 5.91E-02 7.92E-02 
477 quinapril MCF7 6.48E-01 5.94E-02 7.96E-02 
478 gliquidone MCF7 6.48E-01 6.10E-02 8.12E-02 
479 pergolide MCF7 6.48E-01 6.44E-02 8.52E-02 
480 ouabain MCF7 6.47E-01 6.62E-02 8.73E-02 
481 baclofen MCF7 6.47E-01 6.64E-02 8.74E-02 
482 proguanil MCF7 6.47E-01 6.80E-02 8.91E-02 
483 methocarbamol MCF7 6.47E-01 6.86E-02 8.98E-02 
484 diethylcarbamazin
e 
MCF7 6.47E-01 6.89E-02 9.02E-02 
485 sphingosine MCF7 6.47E-01 6.90E-02 9.02E-02 
486 piceatannol MCF7 6.47E-01 7.00E-02 9.13E-02 
487 lofexidine MCF7 6.47E-01 7.03E-02 9.16E-02 
488 diazoxide MCF7 6.47E-01 7.05E-02 9.19E-02 
489 acepromazine MCF7 6.47E-01 7.14E-02 9.28E-02 
490 lorazepam MCF7 6.47E-01 7.16E-02 9.29E-02 
491 yohimbine MCF7 6.47E-01 7.20E-02 9.33E-02 
492 pefloxacin MCF7 6.46E-01 7.36E-02 9.51E-02 
493 diphenoxylate MCF7 6.46E-01 7.49E-02 9.65E-02 
494 spironolactone MCF7 6.46E-01 7.53E-02 9.68E-02 
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495 gliclazide MCF7 6.46E-01 7.56E-02 9.71E-02 
496 atropine MCF7 6.46E-01 8.03E-02 1.02E-01 
497 hexylcaine MCF7 6.45E-01 8.81E-02 1.10E-01 
498 sotalol MCF7 6.45E-01 8.95E-02 1.12E-01 
499 primidone MCF7 6.44E-01 9.10E-02 1.13E-01 
500 batimastat MCF7 6.44E-01 9.17E-02 1.14E-01 
501 rifaximin MCF7 6.44E-01 9.18E-02 1.14E-01 
502 zopiclone MCF7 6.44E-01 9.27E-02 1.15E-01 
503 domperidone MCF7 6.44E-01 9.29E-02 1.15E-01 
504 nilutamide MCF7 6.44E-01 9.30E-02 1.15E-01 
505 ritodrine MCF7 6.44E-01 9.37E-02 1.16E-01 
506 tubocurarine MCF7 6.44E-01 9.39E-02 1.16E-01 
507 allopurinol MCF7 6.44E-01 9.49E-02 1.17E-01 
508 piretanide MCF7 6.44E-01 9.57E-02 1.18E-01 
509 orlistat MCF7 6.44E-01 9.58E-02 1.18E-01 
510 dicoumarol MCF7 6.44E-01 9.61E-02 1.18E-01 
511 nomifensine MCF7 6.44E-01 9.62E-02 1.19E-01 
512 cinnarizine MCF7 6.44E-01 9.92E-02 1.22E-01 
513 phentolamine MCF7 6.44E-01 1.00E-01 1.23E-01 
514 flurandrenolide MCF7 6.43E-01 1.01E-01 1.24E-01 
515 argatroban MCF7 6.43E-01 1.02E-01 1.24E-01 
516 promethazine MCF7 6.43E-01 1.02E-01 1.25E-01 
517 brimonidine MCF7 6.43E-01 1.03E-01 1.25E-01 
518 ephedrine MCF7 6.43E-01 1.06E-01 1.28E-01 
519 ethionamide MCF7 6.43E-01 1.06E-01 1.28E-01 
520 formoterol MCF7 6.43E-01 1.06E-01 1.28E-01 
521 methysergide MCF7 6.43E-01 1.07E-01 1.29E-01 
522 betazole MCF7 6.43E-01 1.08E-01 1.31E-01 
523 guanadrel MCF7 6.43E-01 1.10E-01 1.32E-01 
524 pargyline MCF7 6.42E-01 1.11E-01 1.33E-01 
525 fenoldopam MCF7 6.42E-01 1.14E-01 1.36E-01 
526 farnesol MCF7 6.42E-01 1.15E-01 1.37E-01 
527 cetirizine MCF7 6.42E-01 1.16E-01 1.39E-01 
528 osi-930 MCF7 6.42E-01 1.17E-01 1.40E-01 
529 butenafine MCF7 6.42E-01 1.18E-01 1.40E-01 
530 salbutamol MCF7 6.42E-01 1.19E-01 1.42E-01 
531 bethanechol MCF7 6.42E-01 1.20E-01 1.42E-01 
532 cilastatin MCF7 6.42E-01 1.21E-01 1.44E-01 
533 memantine MCF7 6.41E-01 1.24E-01 1.47E-01 
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534 diclofenamide MCF7 6.41E-01 1.25E-01 1.47E-01 
535 pantoprazole MCF7 6.41E-01 1.25E-01 1.48E-01 
536 tamibarotene MCF7 6.41E-01 1.28E-01 1.51E-01 
537 mdl-29951 MCF7 6.41E-01 1.28E-01 1.51E-01 
538 buspirone MCF7 6.41E-01 1.31E-01 1.54E-01 
539 methimazole MCF7 6.41E-01 1.32E-01 1.55E-01 
540 axitinib MCF7 6.40E-01 1.37E-01 1.60E-01 
541 etretinate MCF7 6.40E-01 1.40E-01 1.63E-01 
542 apomorphine MCF7 6.40E-01 1.41E-01 1.65E-01 
543 cimetidine MCF7 6.40E-01 1.46E-01 1.69E-01 
544 dyphylline MCF7 6.39E-01 1.48E-01 1.71E-01 
545 metolazone MCF7 6.39E-01 1.51E-01 1.74E-01 
546 tranylcypromine MCF7 6.39E-01 1.52E-01 1.75E-01 
547 meloxicam MCF7 6.39E-01 1.58E-01 1.81E-01 
548 perindopril MCF7 6.39E-01 1.59E-01 1.82E-01 
549 quinine MCF7 6.38E-01 1.62E-01 1.84E-01 
550 phenindione MCF7 6.38E-01 1.63E-01 1.86E-01 
551 pheniramine MCF7 6.38E-01 1.70E-01 1.92E-01 
552 alclometasone MCF7 6.38E-01 1.74E-01 1.97E-01 
553 entacapone MCF7 6.38E-01 1.75E-01 1.97E-01 
554 pyridoxine MCF7 6.37E-01 1.76E-01 1.99E-01 
555 flumazenil MCF7 6.37E-01 1.78E-01 2.00E-01 
556 neostigmine MCF7 6.37E-01 1.82E-01 2.03E-01 
557 dolasetron MCF7 6.37E-01 1.83E-01 2.05E-01 
558 mepenzolate MCF7 6.36E-01 1.93E-01 2.14E-01 
559 alizapride MCF7 6.36E-01 1.95E-01 2.16E-01 
560 levonorgestrel MCF7 6.36E-01 2.02E-01 2.22E-01 
561 oxyphenbutazone MCF7 6.36E-01 2.02E-01 2.22E-01 
562 ropinirole MCF7 6.36E-01 2.03E-01 2.23E-01 
563 theobromine MCF7 6.35E-01 2.06E-01 2.27E-01 
564 promazine MCF7 6.35E-01 2.07E-01 2.27E-01 
565 trimethoprim MCF7 6.35E-01 2.10E-01 2.30E-01 
566 rivastigmine MCF7 6.35E-01 2.18E-01 2.39E-01 
567 naftifine MCF7 6.34E-01 2.24E-01 2.44E-01 
568 nizatidine MCF7 6.34E-01 2.27E-01 2.47E-01 
569 mephentermine MCF7 6.34E-01 2.27E-01 2.47E-01 
570 iloprost MCF7 6.34E-01 2.33E-01 2.53E-01 
571 hydrochlorothiazi
de 
MCF7 6.34E-01 2.35E-01 2.55E-01 
		
45 
572 digitoxin MCF7 6.34E-01 2.39E-01 2.59E-01 
573 roxithromycin MCF7 6.33E-01 2.45E-01 2.64E-01 
574 amantadine MCF7 6.33E-01 2.53E-01 2.72E-01 
575 misoprostol MCF7 6.32E-01 2.66E-01 2.84E-01 
576 milrinone MCF7 6.32E-01 2.71E-01 2.89E-01 
577 emedastine MCF7 6.32E-01 2.73E-01 2.92E-01 
578 dimenhydrinate MCF7 6.32E-01 2.73E-01 2.92E-01 
579 ttnpb MCF7 6.32E-01 2.74E-01 2.92E-01 
580 carbenoxolone MCF7 6.31E-01 2.81E-01 2.99E-01 
581 guanfacine MCF7 6.31E-01 2.83E-01 3.01E-01 
582 levobunolol MCF7 6.30E-01 2.97E-01 3.14E-01 
583 xylometazoline MCF7 6.30E-01 3.02E-01 3.18E-01 
584 phenolphthalein MCF7 6.30E-01 3.07E-01 3.24E-01 
585 chloropyramine MCF7 6.30E-01 3.13E-01 3.30E-01 
586 trimethadione MCF7 6.29E-01 3.14E-01 3.30E-01 
587 alverine MCF7 6.29E-01 3.20E-01 3.36E-01 
588 leflunomide MCF7 6.29E-01 3.26E-01 3.42E-01 
589 1-benzylimidazole MCF7 6.29E-01 3.28E-01 3.44E-01 
590 fomepizole MCF7 6.29E-01 3.30E-01 3.46E-01 
591 bretylium MCF7 6.28E-01 3.43E-01 3.58E-01 
592 aniracetam MCF7 6.28E-01 3.49E-01 3.63E-01 
593 sulpiride MCF7 6.27E-01 3.65E-01 3.79E-01 
594 zaleplon MCF7 6.27E-01 3.74E-01 3.88E-01 
595 diazepam MCF7 6.27E-01 3.74E-01 3.88E-01 
596 darifenacin MCF7 6.26E-01 3.77E-01 3.91E-01 
597 butalbital MCF7 6.26E-01 3.94E-01 4.07E-01 
598 felodipine MCF7 6.25E-01 4.00E-01 4.13E-01 
599 asenapine MCF7 6.25E-01 4.12E-01 4.24E-01 
600 tenoxicam MCF7 6.24E-01 4.31E-01 4.42E-01 
601 ziprasidone MCF7 6.24E-01 4.40E-01 4.51E-01 
602 diphenhydramine MCF7 6.23E-01 4.61E-01 4.71E-01 
603 loxapine MCF7 6.20E-01 5.29E-01 5.37E-01 
604 pranlukast MCF7 6.19E-01 5.36E-01 5.44E-01 
605 diflorasone MCF7 6.18E-01 5.63E-01 5.70E-01 
606 naphazoline MCF7 6.18E-01 5.68E-01 5.75E-01 
607 pralidoxime MCF7 6.18E-01 5.71E-01 5.78E-01 
608 nortriptyline MCF7 6.17E-01 5.83E-01 5.89E-01 
609 methoxamine MCF7 6.14E-01 6.46E-01 6.51E-01 
610 acarbose MCF7 6.14E-01 6.54E-01 6.58E-01 
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611 alrestatin MCF7 6.06E-01 7.89E-01 7.91E-01 
612 chlorcyclizine MCF7 6.00E-01 8.75E-01 8.76E-01 
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Appendix B 
Appendix B-1 Over-represented pathways of mutation-associated genes 
(MAG-UP) and differentially expressed genes (DEG-UP) for breast cancer  
 
*MAG-UP (247) Count P-value FDR 
Pathways in cancer 398 5.56E-39 9.73E-37 
Cell cycle 124 1.07E-32 9.33E-31 
Hepatitis B 146 6.25E-26 3.64E-24 
Pancreatic cancer 66 9.93E-26 4.34E-24 
Chronic myeloid leukemia 73 1.58E-25 5.52E-24 
Prostate cancer 89 5.30E-25 1.55E-23 
Spliceosome 132 3.21E-22 8.02E-21 
Endometrial cancer 52 1.13E-20 2.48E-19 
Small cell lung cancer 86 1.30E-20 2.54E-19 
Viral carcinogenesis 206 6.66E-20 1.16E-18 
Colorectal cancer 62 7.42E-20 1.18E-18 
Melanoma 71 4.78E-17 6.97E-16 
FoxO signaling pathway 134 6.65E-17 8.96E-16 
ErbB signaling pathway 87 6.13E-16 7.67E-15 
Epstein+AC0-Barr virus infection 202 7.42E-16 8.66E-15 
Acute myeloid leukemia 57 9.70E-16 1.06E-14 
Neurotrophin signaling pathway 120 2.31E-15 2.38E-14 
Non+AC0-small cell lung cancer 56 1.07E-14 1.04E-13 
HTLV+AC0-I infection 261 1.42E-14 1.31E-13 
Glioma 65 1.78E-14 1.55E-13 
MAPK signaling pathway 257 2.56E-13 2.08E-12 
Proteoglycans in cancer 204 2.62E-13 2.08E-12 
PI3K+AC0-Akt signaling pathway 347 3.48E-13 2.65E-12 
Bladder cancer 38 5.61E-13 4.08E-12 
p53 signaling pathway 68 5.83E-13 4.08E-12 
Thyroid hormone signaling pathway 119 1.17E-12 7.90E-12 
Renal cell carcinoma 66 3.84E-12 2.49E-11 
Apoptosis 86 6.02E-12 3.76E-11 
T cell receptor signaling pathway 104 3.17E-11 1.91E-10 
VEGF signaling pathway 61 1.21E-10 7.04E-10 
Prolactin signaling pathway 72 1.91E-10 1.08E-09 
MicroRNAs in cancer 297 3.78E-10 2.07E-09 
Ras signaling pathway 228 3.21E-09 1.70E-08 
Measles 134 4.32E-09 2.22E-08 
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Central carbon metabolism in cancer 67 5.13E-09 2.57E-08 
Progesterone+AC0-mediated oocyte 
maturation 
88 5.28E-09 2.57E-08 
Toll+AC0-like receptor signaling pathway 106 1.58E-08 7.48E-08 
Hepatitis C 133 2.13E-08 9.79E-08 
Chemokine signaling pathway 189 2.40E-08 1.08E-07 
Non+AC0-alcoholic fatty liver disease 
(NAFLD) 
151 3.82E-08 1.67E-07 
Signaling pathways regulating pluripotency 
of stem cells 
142 6.60E-08 2.82E-07 
Fc epsilon RI signaling pathway 70 7.82E-08 3.26E-07 
mTOR signaling pathway 60 8.47E-08 3.45E-07 
B cell receptor signaling pathway 72 1.14E-07 4.40E-07 
Toxoplasmosis 120 1.16E-07 4.40E-07 
Sphingolipid signaling pathway 120 1.16E-07 4.40E-07 
Shigellosis 65 2.31E-07 8.59E-07 
Choline metabolism in cancer 101 2.78E-07 1.01E-06 
HIF+AC0-1 signaling pathway 103 3.67E-07 1.31E-06 
Chagas disease (American trypanosomiasis) 104 4.20E-07 1.47E-06 
Osteoclast differentiation 131 4.50E-07 1.54E-06 
Focal adhesion 207 5.63E-07 1.89E-06 
TNF signaling pathway 110 9.19E-07 3.03E-06 
Adherens junction 73 9.49E-07 3.07E-06 
Regulation of actin cytoskeleton 215 4.03E-06 1.26E-05 
Thyroid cancer 29 4.04E-06 1.26E-05 
Herpes simplex infection 186 5.31E-06 1.63E-05 
Insulin signaling pathway 140 5.41E-06 1.63E-05 
Oocyte meiosis 113 6.52E-06 1.93E-05 
Fc gamma R+AC0-mediated phagocytosis 91 1.21E-05 3.50E-05 
Bacterial invasion of epithelial cells 78 1.22E-05 3.50E-05 
Epithelial cell signaling in Helicobacter 
pylori infection 
68 1.73E-05 4.89E-05 
Hippo signaling pathway 154 1.95E-05 5.43E-05 
Wnt signaling pathway 140 2.23E-05 6.11E-05 
Influenza A 177 3.41E-05 9.19E-05 
Tuberculosis 179 3.97E-05 1.05E-04 
Amyotrophic lateral sclerosis (ALS) 51 5.03E-05 1.31E-04 
Ubiquitin mediated proteolysis 137 6.69E-05 1.72E-04 
TGF+AC0-beta signaling pathway 80 8.23E-05 2.09E-04 
NOD+AC0-like receptor signaling pathway 57 1.24E-04 3.09E-04 
RIG+AC0-I+AC0-like receptor signaling 
pathway 
70 1.25E-04 3.09E-04 
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Estrogen signaling pathway 100 1.51E-04 3.66E-04 
Natural killer cell mediated cytotoxicity 134 1.94E-04 4.65E-04 
NF+AC0-kappa B signaling pathway 91 2.66E-04 6.30E-04 
Rap1 signaling pathway 211 3.28E-04 7.66E-04 
Fanconi anemia pathway 53 4.08E-04 9.39E-04 
Transcriptional misregulation in cancer 179 4.20E-04 9.53E-04 
Adipocytokine signaling pathway 70 6.09E-04 1.37E-03 
Base excision repair 33 7.94E-04 1.76E-03 
AMPK signaling pathway 124 1.10E-03 2.41E-03 
GnRH signaling pathway 92 1.17E-03 2.54E-03 
Homologous recombination 28 2.39E-03 5.09E-03 
Basal cell carcinoma 55 2.61E-03 5.49E-03 
Type II diabetes mellitus 48 5.72E-03 1.19E-02 
Mismatch repair 23 7.25E-03 1.49E-02 
Jak+AC0-STAT signaling pathway 156 7.39E-03 1.50E-02 
Non+AC0-homologous end+AC0-joining 13 8.93E-03 1.80E-02 
Salmonella infection 86 9.23E-03 1.84E-02 
Aldosterone+AC0-regulated sodium 
reabsorption 
39 1.03E-02 2.02E-02 
Legionellosis 55 1.11E-02 2.15E-02 
Axon guidance 127 1.20E-02 2.30E-02 
Pertussis 75 1.43E-02 2.72E-02 
Carbohydrate digestion and absorption 45 1.85E-02 3.48E-02 
Cytosolic DNA+AC0-sensing pathway 64 2.22E-02 4.14E-02 
Notch signaling pathway 48 2.38E-02 4.39E-02 
 
 
 
 
*DEG-UP (247) Count P-value FDR 
Cell cycle 124 1.89E-16 2.38E-14 
Oocyte meiosis 113 4.06E-09 2.55E-07 
Progesterone+AC0-mediated oocyte 
maturation 
88 3.16E-06 1.33E-04 
Base excision repair 33 8.29E-05 2.61E-03 
DNA replication 36 1.27E-04 3.21E-03 
p53 signaling pathway 68 3.44E-04 7.21E-03 
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Appendix B-2 Over-represented pathways of mutation-associated genes 
(MAG-UP) and differentially expressed genes (DEG-UP) for prostate cancer  
 
*MAG-UP (333) Count P-value FDR 
Pathways in cancer 398 1.40E-22 2.88E-20 
T cell receptor signaling pathway 104 4.91E-17 5.06E-15 
Epstein+AC0-Barr virus infection 202 2.24E-16 1.54E-14 
Acute myeloid leukemia 57 4.37E-15 2.25E-13 
Endometrial cancer 52 6.30E-15 2.60E-13 
Non+AC0-small cell lung cancer 56 3.70E-14 1.27E-12 
Glioma 65 1.07E-13 3.14E-12 
Chronic myeloid leukemia 73 1.66E-13 4.28E-12 
Prostate cancer 89 2.70E-13 6.18E-12 
Viral carcinogenesis 206 3.80E-13 7.83E-12 
Melanoma 71 8.36E-13 1.57E-11 
PI3K+AC0-Akt signaling pathway 347 1.27E-12 2.19E-11 
Pancreatic cancer 66 1.57E-12 2.49E-11 
Primary immunodeficiency 36 4.25E-10 6.26E-09 
HTLV+AC0-I infection 261 6.16E-10 8.46E-09 
Hepatitis B 146 1.11E-09 1.42E-08 
Thyroid hormone signaling pathway 119 1.56E-09 1.89E-08 
Colorectal cancer 62 2.95E-09 3.38E-08 
FoxO signaling pathway 134 3.88E-09 4.21E-08 
Amyotrophic lateral sclerosis (ALS) 51 8.91E-09 9.09E-08 
Proteoglycans in cancer 204 9.27E-09 9.09E-08 
Toxoplasmosis 120 9.73E-09 9.11E-08 
Measles 134 1.86E-08 1.67E-07 
Influenza A 177 2.05E-08 1.73E-07 
Rap1 signaling pathway 211 2.10E-08 1.73E-07 
Synaptic vesicle cycle 63 2.90E-08 2.30E-07 
B cell receptor signaling pathway 72 3.47E-08 2.65E-07 
Ras signaling pathway 228 3.78E-08 2.78E-07 
Thyroid cancer 29 4.57E-08 3.25E-07 
Renal cell carcinoma 66 5.94E-08 4.08E-07 
Bladder cancer 38 1.18E-07 7.81E-07 
ErbB signaling pathway 87 1.22E-07 7.83E-07 
Insulin signaling pathway 140 1.95E-07 1.22E-06 
Osteoclast differentiation 131 2.43E-07 1.47E-06 
Choline metabolism in cancer 101 2.65E-07 1.56E-06 
Small cell lung cancer 86 5.48E-07 3.05E-06 
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Apoptosis 86 5.48E-07 3.05E-06 
Toll+AC0-like receptor signaling pathway 106 5.82E-07 3.16E-06 
Bacterial invasion of epithelial cells 78 7.01E-07 3.70E-06 
VEGF signaling pathway 61 8.36E-07 4.30E-06 
Fc epsilon RI signaling pathway 70 8.69E-07 4.37E-06 
Hepatitis C 133 1.32E-06 6.47E-06 
Tuberculosis 179 1.37E-06 6.58E-06 
Central carbon metabolism in cancer 67 2.79E-06 1.31E-05 
SNARE interactions in vesicular transport 34 2.85E-06 1.31E-05 
Progesterone+AC0-mediated oocyte maturation 88 3.79E-06 1.70E-05 
Neurotrophin signaling pathway 120 4.08E-06 1.79E-05 
MAPK signaling pathway 257 5.53E-06 2.37E-05 
Natural killer cell mediated cytotoxicity 134 5.78E-06 2.43E-05 
Cell cycle 124 6.70E-06 2.76E-05 
Endocytosis 213 1.07E-05 4.33E-05 
Regulation of actin cytoskeleton 215 1.27E-05 5.03E-05 
Endocrine and other factor+AC0-regulated 
calcium reabsorption 
48 1.30E-05 5.06E-05 
Hippo signaling pathway 154 1.43E-05 5.46E-05 
Sphingolipid signaling pathway 120 1.59E-05 5.95E-05 
Jak+AC0-STAT signaling pathway 156 1.75E-05 6.43E-05 
TNF signaling pathway 110 1.83E-05 6.62E-05 
mTOR signaling pathway 60 2.32E-05 8.09E-05 
Viral myocarditis 60 2.32E-05 8.09E-05 
Tight junction 138 3.21E-05 0.0001101
29 
Prolactin signaling pathway 72 3.36E-05 0.0001133
31 
Adherens junction 73 3.91E-05 0.0001298
42 
Long+AC0-term potentiation 67 7.31E-05 0.0002391
17 
Intestinal immune network for IgA production 49 9.34E-05 0.0003006
91 
Fc gamma R+AC0-mediated phagocytosis 91 0.0001058
24 
0.0003323
64 
Chemokine signaling pathway 189 0.0001064
86 
0.0003323
64 
Adipocytokine signaling pathway 70 0.0001138
18 
0.0003499
46 
Long+AC0-term depression 60 0.0001172
22 
0.0003551
14 
Huntington's disease 193 0.0001452 0.0004336
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39 11 
p53 signaling pathway 68 0.0003707
17 
0.0010909
67 
Focal adhesion 207 0.0003971
36 
0.0011521
37 
HIF+AC0-1 signaling pathway 103 0.0004026
89 
0.0011521
37 
Chagas disease (American trypanosomiasis) 104 0.0004453
83 
0.0012568
34 
Allograft rejection 39 0.0004553
19 
0.0012675
1 
Leukocyte transendothelial migration 118 0.0005253
34 
0.0014429
17 
RNA polymerase 32 0.0006880
82 
0.0018650
64 
Lysosome 122 0.0007501
3 
0.0020068
42 
Salmonella infection 86 0.0008153
75 
0.0021534
25 
Hematopoietic cell lineage 87 0.0009056
57 
0.0023615
85 
Shigellosis 65 0.0010220
52 
0.0026317
84 
Signaling pathways regulating pluripotency of 
stem cells 
142 0.0013130
38 
0.0033393
31 
NF+AC0-kappa B signaling pathway 91 0.0013543
96 
0.0033718
41 
Antigen processing and presentation 79 0.0013585
57 
0.0033718
41 
Prion diseases 36 0.0014446 0.0035374
93 
Amphetamine addiction 68 0.0014596
45 
0.0035374
93 
Nucleotide excision repair 47 0.0016605
21 
0.0039775
27 
Transcriptional misregulation in cancer 179 0.0024700
59 
0.0058431
79 
Non+AC0-alcoholic fatty liver disease (NAFLD) 151 0.0024961
15 
0.0058431
79 
Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) 
74 0.0027899
18 
0.0063858
13 
Leishmaniasis 74 0.0027899
18 
0.0063858
13 
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Estrogen signaling pathway 100 0.0030544
3 
0.0069144
24 
Gap junction 89 0.0035698
14 
0.0079932
79 
Herpes simplex infection 186 0.0037468
69 
0.0082995
16 
Autoimmune thyroid disease 54 0.0040949
08 
0.0089739
48 
Graft+AC0-versus+AC0-host disease 43 0.0041712
1 
0.0090449
39 
African trypanosomiasis 34 0.0052281
1 
0.0112186
53 
Type I diabetes mellitus 45 0.0054080
79 
0.0114851
99 
Alcoholism 180 0.0061116
18 
0.0128468
69 
Ubiquitin mediated proteolysis 137 0.0062828
82 
0.0130734
71 
Axon guidance 127 0.0081998
03 
0.0167328
22 
Oocyte meiosis 113 0.0082039
56 
0.0167328
22 
Cocaine addiction 50 0.0096871
58 
0.0195642
6 
Pertussis 75 0.0097827
17 
0.0195654
35 
Cell adhesion molecules (CAMs) 145 0.0102206
52 
0.0202447
53 
Rheumatoid arthritis 91 0.0121070
9 
0.0237529
58 
GnRH signaling pathway 92 0.0130202
3 
0.0253034
66 
Inflammatory bowel disease (IBD) 67 0.0149261
84 
0.0287363
91 
Pathogenic Escherichia coli infection 55 0.0160305
09 
0.0302961
91 
Basal cell carcinoma 55 0.0160305
09 
0.0302961
91 
AMPK signaling pathway 124 0.0164898
43 
0.0307260
2 
cAMP signaling pathway 200 0.0165562
53 
0.0307260
2 
Wnt signaling pathway 140 0.0176626 0.0324866
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69 95 
Proteasome 44 0.0183212
88 
0.0333998
71 
Melanogenesis 101 0.0237213
38 
0.0428648
74 
Platelet activation 131 0.0243563
26 
0.0436295
93 
Notch signaling pathway 48 0.0271316
38 
0.0477702
35 
Type II diabetes mellitus 48 0.0271316
38 
0.0477702
35 
 
 
*DEG-UP (333) Count P-value FDR 
Olfactory transduction 408 1.84E-29 2.06E-27 
Neuroactive ligand+AC0-receptor interaction 275 1.57E-04 8.79E-03 
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Appendix C 
Appendix C-1 Viability of MCF10A, MCF7 and SUM 149 cells exposed to Doxorubicin 
with concentrations ranging from 0.5 µM to 200 µM after 24 h incubation.   
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The relative viability was calculated as relative viability = (experimental absorbance - 
background absorbance)/ (absorbance of untreated controls - background absorbance 
of untreated controls) × 100 %  (means ± SD, n=6).  
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Appendix C-2 Viability of MCF10A, MCF7 and SUM 149 cells exposed to Mefloquine  
with concentrations ranging from 3.125 µM to 100 µM after 24 h incubation. 
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The	relative	viability	was	calculated	as	relative	viability	=	(experimental	absorbance	-	background	absorbance)/	(absorbance	of	untreated	controls	-	background	absorbance	of	untreated	controls)	×	100	%		(means	±	SD,	n=3).	 
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Appendix C-3 Viability of MCF10A, MCF7 and SUM 149 cells exposed to Clotrimazole 
with concentrations ranging from 3.125 µM to 100 µM after 24 h incubation. 
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The relative viability was calculated as relative viability = (experimental absorbance - 
background absorbance)/ (absorbance of untreated controls - background absorbance 
of untreated controls) × 100 % (means ± SD, n=3).  
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Appendix C-4 Viability of MCF10A, MCF7 and SUM 149 cells exposed to Thioridazine 
with concentrations ranging from 3.125 µM to 100 µM after 24 h incubation. 
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The relative viability was calculated as relative viability = (experimental absorbance - 
background absorbance)/ (absorbance of untreated controls - background absorbance 
of untreated controls) × 100 %  (means ± SD, n=3).   
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Appendix C-5 Viability of MCF10A, MCF7 and SUM 149 cells exposed to Fluphenazine 
with concentrations ranging from 3.125 µM to 100 µM after 24 h incubation. 
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The relative viability was calculated as relative viability = (experimental absorbance - 
background absorbance)/ (absorbance of untreated controls - background absorbance 
of untreated controls) × 100 %  (means ± SD, n=3).  
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Appendix C-6 Viability of MCF10A, MCF7 and SUM 149 cells exposed to Triprolidine 
with concentrations ranging from 31.25 µM to 1000 µM after 24 h incubation.  
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The relative viability was calculated as relative viability = (experimental absorbance - 
background absorbance)/ (absorbance of untreated controls - background absorbance of 
untreated controls) × 100 % (means ± SD, n=3).   
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